doxorubicin induced cardiomyopathy
doxorubicin caused cardiomyopathy
doxorubicin therapy accompanies dysfunction cardiomyopathy
indinavir receiving describe features calculi ureteric
indinavir receiving describe features calculi
Pilsicainide due Death Sudden
Pilsicainide due Death Cardiac
Pilsicainide due Death
Pilsicainide due Death Case Pointes Torsades
Pilsicainide due Death Case Pointes de
Pilsicainide due Death Case Pointes
pilsicainide received developed death sudden
pilsicainide received developed death cardiac
pilsicainide received developed death
pilsicainide dose low impaired high produce torsades
pilsicainide dose low impaired high produce torsades de
pilsicainide dose low impaired high produce torsades pointes
pilsicainide concentration high produce torsades
pilsicainide concentration high produce torsades de
pilsicainide concentration high produce torsades pointes
terbinafine combination induced bradycardia
metoprolol combination induced bradycardia
cisplatin induced injury acute
cisplatin induced injury renal
cisplatin induced injury
Cisplatin treatment adopted induce ability affect increase score acute
Cisplatin treatment adopted induce ability affect increase score tubular
Cisplatin treatment adopted induce ability affect increase score necrosis
Cisplatin treatment adopted induce injury acute
Cisplatin treatment adopted induce injury kidney
Cisplatin treatment adopted induce injury
cisplatin receptor injury acute
cisplatin receptor injury kidney
cisplatin receptor injury
cisplatin challenged examine role receptor injury acute
cisplatin challenged examine role receptor injury kidney
cisplatin challenged examine role receptor injury
cisplatin involved induced injury acute
cisplatin involved induced injury kidney
cisplatin involved induced injury
dexmedetomidine bradycardia Vasovagal
dexmedetomidine bradycardia syncope
dexmedetomidine bradycardia
dexmedetomidine administration year syncope bradycardia
aminoglycoside nephrotoxicity
aminoglycoside induced nephrotoxicity
aminoglycosides cause indicate cause glomerular
aminoglycosides cause indicate cause glomerular or
aminoglycosides cause indicate cause glomerular dysfunction tubular
aminoglycosides cause indicate cause glomerular dysfunction
aminoglycoside levels therapy duration increase risk nephrotoxicity
aminoglycoside pathophysiology developing useful induced nephrotoxicity
fluoxetine improved dyskinesias
apomorphine agonist challenge evaluated severity dyskinesias
fluoxetine administration apomorphine agonist challenge evaluated severity dyskinesias
apomorphine induced dyskinesias
fluoxetine treatment was improvement apomorphine induced dyskinesias
fluoxetine transmission reduce dyskinesias
pilocarpine model seizures
pilocarpine produced seizures
pilocarpine induces seizures
pilocarpine induces seizures epilepticus status
pilocarpine induces seizures epilepticus
pilocarpine produced seizures
phenylbutazone non effect investigate designed seizures
sodium salicylate non effect investigate designed seizures
salicylate non effect investigate designed seizures
pilocarpine produced seizures
pilocarpine induced damage seizures
pilocarpine induced damage seizures rats seizure
pilocarpine threshold modulate seizures
Isoproterenol injected induce infarction myocardial acute
Isoproterenol injected induce infarction myocardial
Isoproterenol injected induce infarction
fenfluramines had association PPH
fenfluramines specificity association PPH
fenfluramines specificity association magnitude consistent studies indicating related PPH
fenfluramines related indicating studies consistent magnitude association PPH
fenfluramines related PPH
levodopa effect hypotensive
levodopa effect hypotensive
levodopa competing acid reduced effects hypotensive
levodopa effects hypotensive
levodopa has action hypotensive
phenytoin administration developed failure hepatic
phenytoin administration developed failure
FZP toxocity Signs included salivation convulsions
FZP protected convulsions
FZP doses lower those cause convulsions
amiodarone therapy initiation weeks have failure bradycardia hypothermia
amiodarone therapy initiation weeks have failure bradycardia
amiodarone therapy initiation weeks have failure bradycardia respiratory
amiodarone therapy initiation weeks have failure
haloperidol synthesis Sub catalepsy
haloperidol drugs cause catalepsy
haloperidol NOARG investigate induced catalepsy
haloperidol NOARG NOARG induced catalepsy
angiotensin therapy frequency angio
angiotensin therapy frequency oedema
converting inhibitor frequency angio
converting inhibitor frequency oedema
enzyme inhibitor frequency angio
enzyme inhibitor frequency oedema
inhibitor frequency angio
inhibitor frequency oedema
ACE inhibitors introduction reported bouts angio
ACE inhibitors introduction reported bouts angio oedema
inhibitors introduction reported bouts angio
inhibitors introduction reported bouts angio oedema
ACE angio
ACE angio oedema
inhibitors ACE angio
inhibitors ACE angio oedema
pilocarpine model epilepticus status
pilocarpine model epilepticus
lithium 801 actions model epilepticus status
lithium 801 actions model epilepticus
pilocarpine lithium induced seizures block easy difficult terminate epilepticus status
pilocarpine lithium induced seizures block easy difficult terminate epilepticus
pilocarpine prior anticonvulsants administration induced seizures block easy difficult terminate epilepticus status
pilocarpine prior anticonvulsants administration induced seizures block easy difficult terminate epilepticus
lithium induced seizures block easy difficult terminate epilepticus status
lithium induced seizures block easy difficult terminate epilepticus
pilocarpine 30 epilepticus status
pilocarpine 30 epilepticus
pilocarpine model damage role epilepticus status
pilocarpine model damage role epilepticus
lithium model damage role epilepticus status
lithium model damage role epilepticus
pilocarpine NMDA doses synergistic resulting epilepticus status
pilocarpine NMDA doses synergistic resulting epilepticus
valproate therapy fatty Nonalcoholic
valproate therapy fatty
valproate therapy fatty disease liver
valproate therapy fatty disease
VPA treatment developed obesity
VPA treatment developed child arising disease nonalcoholic
VPA treatment developed child arising disease fatty
VPA treatment developed child arising disease liver
VPA treatment developed child arising disease
VPA treatment developed child arising disease NAFLD
VPA treatment associated suggests obesity hyperinsulinemia
VPA withdrawal reversible suggests obesity hyperinsulinemia
VPA treatment associated suggests obesity
VPA withdrawal reversible suggests obesity
VPA treatment associated development NAFLD
VPA withdrawal reversible suggests associated development NAFLD
VPA treatment associated suggests obesity resistance insulin
VPA treatment associated suggests obesity resistance
VPA withdrawal reversible suggests obesity resistance insulin
VPA withdrawal reversible suggests obesity resistance
cisplatin high induced Efficacy granisetron prevention nausea vomiting
cisplatin high induced Efficacy granisetron prevention nausea
cisplatin prophylaxis administered assess induced nausea vomiting
cisplatin prophylaxis administered assess induced nausea
cisplatin received patients % vomiting
cisplatin received prevented vomiting
dexamethasone lactoferrin effects hypertension
Dexamethasone hypertension
Dex hypertension
Dex administration investigated stress hypertension
Dex induced hypertension
Dex improved reduced induced hypertension
cobalt cardiomyopathy
doxorubicin dogs failure heart
doxorubicin dogs failure
Ethacrynic acid induced convulsions
acid induced convulsions
ethacrynic acid accelerated mouse convulsive
acid accelerated mouse convulsive
ethacrynic acid convulsions
acid convulsions
5 Fluoxetine improves deficits memory
5 Fluoxetine improves deficits
fluorouracil 5 Fluoxetine improves deficits memory
fluorouracil 5 Fluoxetine improves deficits
Phenytoin encephalopathy
phenytoin case seizures encephalopathy
DPH case seizures encephalopathy
gentamicin scavengers effects Mechanisms nephropathy
gentamicin nephropathy
GM gentamicin nephropathy
GM Administration sc days rats induced flow damage tubular
GM Administration sc days rats induced flow damage
GM observed mediated nephropathy
GM effects have differ nephropathy
GM role play have differ nephropathy
aspirin damage renal
aspirin damage
aspirin jj treated p lesions increase rats jJ jj accompanied evidence damage renal
aspirin jj treated p lesions increase rats jJ jj accompanied evidence damage
pilocarpine reticulata Damage epilepticus status
pilocarpine reticulata Damage epilepticus
pilocarpine reticulata Damage
pilocarpine reticulata of
pilocarpine reticulata substantia
pilocarpine reticulata nigra
pilocarpine reticulata pars
pilocarpine reticulata
pilocarpine injection induced epilepticus status
pilocarpine injection induced epilepticus
pilocarpine MK induced seizure
MK induced seizure
801 augments pilocarpine MK induced seizure
pilocarpine 801 effects model seizure
MK effects model seizure
801 effects model seizure
pilocarpine injection induced tonic
pilocarpine injection induced tonic and
pilocarpine injection induced tonic seizure clonic
pilocarpine injection induced tonic seizure
pilocarpine induced seizure
MK seizure
801 did pilocarpine induced seizure
pilocarpine appeared seizure
pilocarpine seizure
pilocarpine treatment augmented seizure
pilocarpine induced seizure augmented treatment pilocarpine seizure
pilocarpine induced seizure
MK seizure
801 treatment pilocarpine seizure
MK seizure pilocarpine treatment augmented seizure
801 treatment augmented seizure
Pilocarpine produced death neuronal
Pilocarpine produced death
pilocarpine induced epilepticus status
pilocarpine induced epilepticus
PEG chemotherapy encephalopathy vasospasm cerebral
PEG chemotherapy encephalopathy vasospasm
asparaginase cytarabine encephalopathy vasospasm cerebral
asparaginase cytarabine encephalopathy vasospasm
cytarabine encephalopathy vasospasm cerebral
cytarabine encephalopathy vasospasm
cytarabine administration sided encephalopathy evidenced changes hallucinations visual
cytarabine administration sided encephalopathy evidenced changes hallucinations
cytarabine administration sided encephalopathy evidenced changes incontinence
cytarabine administration sided vasospasm cerebral
cytarabine administration sided vasospasm
cytarabine administration sided weakness
cytarabine administration sided encephalopathy evidenced changes aphasia
crack use associated ulcers Corneal
crack use associated ulcers
cocaine use associated ulcers Corneal
cocaine use associated ulcers
crack use associated ulcers corneal
crack use associated ulcers
cocaine use associated ulcers corneal
cocaine use associated ulcers
crack use associated development ulcers corneal
crack use associated development ulcers
cocaine use associated development ulcers corneal
cocaine use associated development ulcers
artesunate described Cases anemia hemolytic
artesunate described Cases anemia
suxamethonium pressure Increase fasciculations muscle
suxamethonium pressure Increase fasciculations
suxamethonium caused fasciculations muscle
suxamethonium caused fasciculations
suxamethonium caused significantly fasciculations muscle
suxamethonium caused significantly fasciculations
suxamethonium incidence inhibits kg fasciculations muscle
suxamethonium incidence inhibits kg fasciculations
pentobarbital denopamine Improvement failure cardiac
pentobarbital denopamine Improvement failure
methotrexate enhancement images patients leukoencephalopathy
warfarin fibrillation aged People rate hemorrhage
warfarin 76 aged people determine incidence hemorrhage
warfarin use obtained strokes MEASUREMENTS Information episodes bleeding
warfarin rate low high rate hemorrhage
warfarin treatment is demonstrating low high rate hemorrhage
picrotoxin antagonism relationships Structure seizures
picrotoxin induced seizures
picrotoxin diazepam 8 seizures
chlorpromazine induced syndrome extrapyramidal
chlorpromazine induced syndrome
chlorpromazine plays EPS
chlorpromazine treated gene 59 EPS
chlorpromazine treated gene 59 EPS
remifentanil i anesthesia induced anesthesia hypotension
propofol anesthesia induced anesthesia hypotension
remifentanil caused anesthesia hypotension
propofol caused anesthesia hypotension
remifentanil infusion rates using using period achieved hypotension
remifentanil dose rates using using period achieved hypotension
remifentanil doses hypotension allowed provided management using anesthesia hypotension
remifentanil doses hypotension
indinavir treated leukocyturia associated function impaired
indinavir treated leukocyturia associated function renal
indinavir treated leukocyturia associated function
indinavir monitor study DESIGN nephrotoxicity
indinavir treated children DESIGN nephrotoxicity
indinavir discontinued nephrotoxicity
Indinavir monitored nephrotoxicity
indinavir L curve area years age leukocyturia factors children monitored nephrotoxicity
enflurane halothane induced hypotension
isoflurane halothane induced hypotension
labetalol induced hypotension
halothane induced hypotension
enflurane halothane studied feasibility using agent hypotensive
isoflurane halothane studied feasibility using agent hypotensive
labetalol using agent hypotensive
halothane studied feasibility using agent hypotensive
E % 0 concentration + 0 concentration hypotension
I % concentration + 0 concentration hypotension
H concentration hypotension
isoflurane group level returned rose hypotension
isoflurane group level returned rose hypotension
labetalol induces hypotension
methoxyflurane acidosis Hepatitis tubular renal
methoxyflurane acidosis Hepatitis tubular
methoxyflurane acidosis
methoxyflurane acidosis Hepatitis
methoxyflurane anesthesia operated man year acidosis renal
methoxyflurane anesthesia operated man year acidosis tubular
methoxyflurane anesthesia operated man year acidosis
methadone receiving users syndrome long
methadone receiving users syndrome QT
methadone receiving users syndrome
methadone treatment prolongation QT
methadone treatment prolongation interval
methadone treatment prolongation
methadone dose addition considered factors prolongation QT
methadone dose addition considered factors prolongation
methadone patients prolongation QT
methadone patients prolongation interval
methadone patients prolongation
Methadone dose potassium contribute QT
Methadone dose potassium contribute QT prolongation
methadone doses occur syndrome Long
methadone doses occur syndrome QT
methadone doses occur syndrome
alendronate administration Diffuse pain
alendronate administration admitted out clinic pain
doxorubicin doses treatment stress cardiotoxicity
doxorubicin cardiotoxicity
DOX doxorubicin cardiotoxicity
DOX dose associated disarrangement necrosis
DOX dose induced cardiotoxicity
D showed necrosis tubular
D showed necrosis
AmB showed necrosis tubular
AmB showed necrosis
scopolamine induced amnesia
cocaine patients difficult infarction myocardial
cocaine patients difficult infarction
cocaine patients difficult infarction MI
cocaine pain admitted exclusion MI
cocaine use admitted MI
cocaine patients MB CK associated pain MI
haloperidol induced catalepsy
erythromycin Cotrimoxazole reported episodes manic
Cotrimoxazole reported episodes manic
metronidazole Cotrimoxazole reported episodes manic
clarithromycin showed most associated development mania
ciprofloxacin clarithromycin showed most associated development mania
HCTZ combinations lower incidence hypokalemia
HCTZ monotherapies lower incidence hypokalemia
HCTZ therapies associated associated hypokalemia
HCTZ hypokalemia
contrast material injected developed failure acute
contrast material injected developed failure renal
contrast material injected developed failure
contrast material injected developed failure ARF
misoprostol administration associated Delirium
misoprostol discontinued improved delirium
misoprostol therapy resulted patient experienced delirium
oral contraceptives associated thromboembolism venous
oral contraceptives associated thromboembolism
contraceptives associated thromboembolism venous
contraceptives associated thromboembolism
oral contraceptives containing used women higher incidence thromboembolism venous
oral contraceptives containing used women higher incidence thromboembolism
contraceptives containing used women higher incidence thromboembolism venous
contraceptives containing used women higher incidence thromboembolism
oral contraceptives containing used women higher incidence thromboembolism VTE
contraceptives containing used women higher incidence thromboembolism VTE
OCs contraceptives containing used women higher incidence thromboembolism venous
OCs contraceptives containing used women higher incidence thromboembolism
OCs contraceptives containing used women higher incidence thromboembolism VTE
OCs users gestodene progestagens containing used women higher incidence thromboembolism venous
OCs users gestodene progestagens containing used women higher incidence thromboembolism
OCs users gestodene progestagens containing used women higher incidence thromboembolism VTE
OC VTE
OC preparations users estimate incidence VTE
OC preparations users estimate did study calculate ratios VTE
OC types use associated VTE ratios calculate study did estimate incidence VTE
OC types use associated VTE
OCs progestagen users VTE
OCs use associated VTE
OC users 10 rate VTE
OCs generation 10 rate VTE
OCs users VTE
OCs generation users showed risk VTE
OCs odds 3 ratios VTE
carbamazepine induced myocarditis eosinophilic fulminant
carbamazepine induced myocarditis eosinophilic
carbamazepine induced myocarditis
carbamazepine induced myocarditis eosinophilic hypersensitivity
carbamazepine emphasis mechanisms hypersensitivity drug
carbamazepine emphasis mechanisms hypersensitivity
carbamazepine effect necrotizing fatal eosinophilic myocarditis
carbamazepine effect necrotizing fatal eosinophilic hypersensitivity
carbamazepine administration secondary case myocarditis
carbamazepine administration secondary case myocarditis hypersensitivity
carbamazepine myocarditis
Viracept cause beat known bradycardia
Viracept patient occurred Bradycardia
Amoxicillin stands drug related DILI
clavulanate stands drug related DILI
Nifedipine induced bradycardia
nifedipine induces tachycardia
Morphine induced seizures
morphine sulfate course analgesia neonates suffered seizures
sulfate course analgesia neonates suffered seizures
morphine received kg kg hr had seizures
morphine cessation stopped ruled reasons seizures
morphine cessation stopped convulsions
norpethidine cause resulting attack irritability seizure
sumatriptan colitis Ischemic
sumatriptan colitis
sumatriptan treated migraine patients report development cases colitis ischemic
sumatriptan treated migraine patients report development cases colitis
Diazinon associated cancer lung
Diazinon associated cancer
diazinon associated examined associated cancer lung
diazinon associated examined associated cancer
diazinon days % use 41 60 LT number observed risks lung
diazinon days % use 41 60 LT number observed risks cancer
diazinon evaluation CONCLUSIONS provides evidence association risk lung
diazinon evaluation CONCLUSIONS provides evidence association risk cancer
pentylenetetrazole induced damage seizures
pentylenetetrazole observed impairment cognitive
pentylenetetrazole observed impairment
pentylenetetrazole observed designed evaluate seizures
theophylline reporting nausea tremors
theophylline reporting nausea vomiting
theophylline reporting nausea
PAN rats proteinuric
Succinylcholine apnoea
succinylcholine apnoea
telaprevir treated Rhabdomyolysis
simvastatin telaprevir treated Rhabdomyolysis
Simvastatin concentration increased related times toxicity muscle
Simvastatin concentration increased related times toxicity
statin patient toxicity muscle
statin patient toxicity
statin concentration related times toxicity muscle
statin concentration related times toxicity
gentamicin alkylxanthines Effect failure acute
gentamicin alkylxanthines Effect failure renal
gentamicin alkylxanthines Effect failure
gentamicin injections developing failure acute
gentamicin injections developing failure renal
gentamicin injections developing failure
gentamicin role ARF
Prednisone induces anxiety
prednisone produces anxiety
PDN prednisone produces anxiety
PDN groups documented Anxiety
PDN induced anxiety
3 users Depression impulsiveness
4 3 users Depression impulsiveness
methylenedioxymethamphetamine Depression impulsiveness
MDMA methylenedioxymethamphetamine Depression impulsiveness
ecstasy MDMA methylenedioxymethamphetamine Depression impulsiveness
3 users Depression
4 3 users Depression
methylenedioxymethamphetamine Depression
MDMA methylenedioxymethamphetamine Depression
ecstasy MDMA methylenedioxymethamphetamine Depression
ecstasy users generation prognosis cause Given record memory levels impulsiveness
ecstasy users generation prognosis cause Given record memory levels impulsiveness disturbance sleep
ecstasy users generation prognosis cause Given record memory levels impulsiveness disturbance
ecstasy users generation prognosis cause Given record memory levels impulsiveness depression
Meloxicam induced toxicity liver
Meloxicam induced toxicity
meloxicam due hepatitis
meloxicam administration occurred hepatitis
meloxicam administration occurred associated suggesting mechanism hypersensitivity
meloxicam toxicity liver
meloxicam toxicity
meloxicam toxicity case demonstrates potential drug induce damage hepatic
meloxicam toxicity case demonstrates potential drug induce damage
propranolol induced block sinus Alternating
propranolol induced block sinus
propranolol induced block rhythm
propranolol induced block sinoatrial
propranolol induced block
propranolol daily year Alternating
propranolol daily year Alternating observed rhythm sinus
propranolol daily year Alternating observed rhythm
propranolol daily year Alternating observed rhythm sinoatrial
propranolol daily year Alternating observed rhythm S
propranolol daily year Alternating observed rhythm S A
propranolol daily year Alternating observed block
propranolol withdrawal disappeared seen restarted 2 S
propranolol withdrawal disappeared seen block A
propranolol withdrawal disappeared seen block
lithium insipidus nephrogenic
lithium insipidus diabetes
lithium insipidus
Lithium induces insipidus nephrogenic
Lithium induces insipidus diabetes
Lithium induces insipidus
Lithium induces insipidus NDI
lithium induced polyuria
lithium localization expression AQP preserves prevents development polyuria
lithium therapy associated polyuria
lithium localization expression AQP NDI
lithium therapy associated polyuria development prevents preserves AQP NDI
olanzapine 2 4 were scores Extrapyramidal
olanzapine 2 4 were scores symptom
risperidone 4 were scores Extrapyramidal
risperidone 4 were scores symptom
olanzapine occurred gain weight
olanzapine occurred gain
olanzapine occurred gain weight
olanzapine occurred gain
risperidone occurred gain weight
risperidone occurred gain
risperidone % occurred gain weight
risperidone % occurred gain
olanzapine greater caused gain weight
olanzapine greater caused gain
olanzapine greater gain weight
olanzapine greater gain
lithium induced insipidus nephrogenic
lithium induced insipidus diabetes
lithium induced insipidus
lithium precipitated coma Hyperosmolar
lithium precipitated coma nonketotic
lithium precipitated coma
lithium treated depression history 10 man admitted hyperosmolar
lithium treated depression history 10 man admitted hyperosmolar coma nonketotic
lithium treated depression history 10 man admitted hyperosmolar coma
lithium likely insipidus induced indicated remained polyuric
lithium likely insipidus nephrogenic
lithium likely insipidus diabetes
lithium likely insipidus
ouabain induced mania
ouabain administration suggested mimic symptoms mania bipolar
ouabain administration suggested mimic symptoms mania
ouabain induced mania
ouabain like provide test disorder bipolar
ouabain like provide test disorder
Zolmitriptan secondary syndrome Takotsubo
Zolmitriptan secondary syndrome
Zolmitriptan secondary apical
Zolmitriptan secondary apical syndrome ballooning
Zolmitriptan secondary apical syndrome
zolmitriptan secondary revealed associated TS
zolmitriptan secondary cases vasospasm coronary
zolmitriptan secondary cases vasospasm artery
zolmitriptan secondary cases vasospasm
paclitaxel epirubicin chemotherapy result block atrioventricular
paclitaxel epirubicin chemotherapy result block
epirubicin chemotherapy result block atrioventricular
epirubicin chemotherapy result block
Flumazenil induces seizures
diazepam intoxications induces seizures
cocaine induces seizures
flumazenil Administration unmask seizures
cocaine seizures
Flumazenil unmask seizures
diazepam intoxications increase unmask seizures
cocaine model increase unmask seizures
quinacrine hydrochloride ingesting rats heart involving thrombosis Atrial
quinacrine hydrochloride ingesting rats heart involving thrombosis
hydrochloride ingesting rats heart involving thrombosis Atrial
hydrochloride ingesting rats heart involving thrombosis
quinacrine hydrochloride treated Rats developed incidence thrombosis atrial
quinacrine hydrochloride treated Rats developed incidence thrombosis
hydrochloride treated Rats developed incidence thrombosis atrial
hydrochloride treated Rats developed incidence thrombosis
quinacrine hydrochloride nitrite rats percent had have thrombosis atrial
quinacrine hydrochloride nitrite rats percent had have thrombosis
hydrochloride nitrite rats percent had have thrombosis atrial
hydrochloride nitrite rats percent had have thrombosis
cyclosporine reports precipitated thrombotic
cyclosporine reports precipitated microangiopathy
tacrolimus use risk call patients SSc
CHP concentration relationship pain
CHP cream closest tolerance pain
lindane effect studied measuring onset seizures
lindane administration min animals suffered convulsions
aminoglycoside antibiotics injection failure acute
aminoglycoside antibiotics injection failure renal
aminoglycoside antibiotics injection failure
tacrolimus patient therapy case neuropathy optic
tacrolimus patient therapy case neuropathy
FK tacrolimus patient therapy case neuropathy optic
FK tacrolimus patient therapy case neuropathy
506 FK tacrolimus patient therapy case neuropathy optic
506 FK tacrolimus patient therapy case neuropathy
tacrolimus receiving patient report case neuropathy optic
tacrolimus receiving patient report case neuropathy
FK tacrolimus receiving patient report case neuropathy optic
FK tacrolimus receiving patient report case neuropathy
506 FK tacrolimus receiving patient report case neuropathy optic
506 FK tacrolimus receiving patient report case neuropathy
Tacrolimus agents associated toxicity optic
Tacrolimus agents associated toxicity nerve
Tacrolimus agents associated toxicity
nitric deficiency induced hypertension
oxide deficiency induced hypertension
NO deficiency induced hypertension
nitric oxide derived hypertension
oxide derived hypertension
NO oxide derived hypertension
NO removal created hypertension
NO deficiency increases make form hypertension
pilocarpine produced seizures
Pilocarpine reproduces provides studying mechanisms buildup activity convulsive
Pilocarpine reproduces provides studying generalization seizures
pilocarpine produced seizures
pilocarpine doses kg activity inhibitor micrograms resulted seizures
pilocarpine threshold reduction convulsions
pilocarpine observed formation related seizure
pilocarpine produced seizures
pilocarpine kg produced seizures
pilocarpine kg produced convulsions
pilocarpine threshold induced subjected seizures
doxorubicin kg dose resulted albuminuria
isoproterenol 832 CD induced ischemia myocardial
isoproterenol 832 CD induced ischemia
isoproterenol 832 Effects induced studied ischemia myocardial
isoproterenol 832 Effects induced studied ischemia
ISO isoproterenol 832 Effects induced studied ischemia myocardial
ISO isoproterenol 832 Effects induced studied ischemia
ISO infusion improves ischemia myocardial
ISO infusion improves ischemia
S 53482 BACKGROUND 23121 N herbicides embryolethality
23121 N herbicides embryolethality
S 53482 BACKGROUND 23121 teratogenicity defects ventricular
S 53482 BACKGROUND 23121 teratogenicity defects septal
S 53482 BACKGROUND 23121 teratogenicity defects
23121 teratogenicity defects ventricular
23121 teratogenicity defects septal
23121 teratogenicity defects
S BACKGROUND 23121 teratogenicity
53482 BACKGROUND 23121 teratogenicity
S BACKGROUND 23121 retardation growth
S BACKGROUND 23121 retardation
53482 BACKGROUND 23121 retardation growth
53482 BACKGROUND 23121 retardation
S BACKGROUND 23121 N herbicides embryolethality
53482 BACKGROUND 23121 N herbicides embryolethality
S BACKGROUND 23121 teratogenicity defects ventricular
S BACKGROUND 23121 teratogenicity defects septal
S BACKGROUND 23121 teratogenicity defects
53482 BACKGROUND 23121 teratogenicity defects ventricular
53482 BACKGROUND 23121 teratogenicity defects septal
53482 BACKGROUND 23121 teratogenicity defects
S 53482 BACKGROUND 23121 teratogenicity
23121 teratogenicity
S 53482 BACKGROUND 23121 retardation growth
S 53482 BACKGROUND 23121 retardation
23121 retardation growth
23121 retardation
S kg administration resulted incidence death embryonic
S kg administration resulted incidence death
23121 800 mg kg administration resulted incidence death embryonic
23121 800 mg kg administration resulted incidence death
S exposure following observed resulted incidence death embryonic
S exposure following observed resulted incidence death
23121 exposure following observed resulted incidence death embryonic
23121 exposure following observed resulted incidence death
S kg administration resulted incidence death defect ventricular
S kg administration resulted incidence death defect septal
S kg administration resulted incidence death defect
23121 800 mg kg administration resulted incidence death defect ventricular
23121 800 mg kg administration resulted incidence death defect septal
23121 800 mg kg administration resulted incidence death defect
S exposure following observed resulted incidence death defect ventricular
S exposure following observed resulted incidence death defect septal
S exposure following observed resulted incidence death defect
23121 exposure following observed resulted incidence death defect ventricular
23121 exposure following observed resulted incidence death defect septal
23121 exposure following observed resulted incidence death defect
S results CONCLUSIONS teratogenic
53482 S results CONCLUSIONS teratogenic
S 53482 S results CONCLUSIONS teratogenic
23121 teratogenic
calcium therapy Etiology hypercalcemia
carbonate therapy Etiology hypercalcemia
calcium carbonate switching hypercalcemic
carbonate switching hypercalcemic
capsaicin mastitis
Cocaine induced ischemia myocardial
Cocaine induced ischemia
cocaine induced ischemia myocardial
cocaine induced ischemia
Amlodipine effect Rare Going Dysguesia
amlodipine dysguesia
amlodipine cause dysguesia
amlodipine dysguesia
Penicillamine related dermatitis lichenoid
Penicillamine related dermatitis
penicillamine interrupted appearance dermatitis lichenoid
penicillamine interrupted appearance dermatitis
doxorubicin cardiotoxicity
Propylthiouracil induced damage hepatic
Propylthiouracil induced damage
propylthiouracil cases observed damage liver
propylthiouracil cases observed damage
warfarin users 0 MB TIA RESULTS analysis ICH
warfarin users 0 MB frequent TIA vs ICH
warfarin MB excess users nonusers ICH
warfarin users none 0 nonusers ICH
warfarin users ICH
warfarin users MB excess CONCLUSIONS suggests increase associated ICH
warfarin risk increase suggests CONCLUSIONS excess MB users ICH
warfarin risk increase associated ICH
remoxipride metabolites apoptosis Induction + 19 induced anemia aplastic
remoxipride metabolites apoptosis Induction + 19 induced anemia
remoxipride relevance cells 19 induced anemia aplastic
remoxipride relevance cells 19 induced anemia
remoxipride -LSB- agent associated anemia aplastic
remoxipride -LSB- agent associated anemia
S -LSB- agent associated anemia aplastic
S -LSB- agent associated anemia
- -LSB- agent associated anemia aplastic
- -LSB- agent associated anemia
3 - -LSB- agent associated anemia aplastic
3 - -LSB- agent associated anemia
bromo -LSB- agent associated anemia aplastic
bromo -LSB- agent associated anemia
N bromo -LSB- agent associated anemia aplastic
N bromo -LSB- agent associated anemia
-LSB- -LSB- agent associated anemia aplastic
-LSB- -LSB- agent associated anemia
1 -LSB- -LSB- agent associated anemia aplastic
1 -LSB- -LSB- agent associated anemia
ethyl 1 -LSB- -LSB- agent associated anemia aplastic
ethyl 1 -LSB- -LSB- agent associated anemia
2 1 -LSB- -LSB- agent associated anemia aplastic
2 1 -LSB- -LSB- agent associated anemia
pyrrolidinyl 2 1 -LSB- -LSB- agent associated anemia aplastic
pyrrolidinyl 2 1 -LSB- -LSB- agent associated anemia
methyl -RSB- -LSB- -LSB- agent associated anemia aplastic
methyl -RSB- -LSB- -LSB- agent associated anemia
-RSB- -LSB- -LSB- agent associated anemia aplastic
-RSB- -LSB- -LSB- agent associated anemia
2 -LSB- agent associated anemia aplastic
2 -LSB- agent associated anemia
6 2 -LSB- agent associated anemia aplastic
6 2 -LSB- agent associated anemia
dimethoxybenz -LSB- agent associated anemia aplastic
dimethoxybenz -LSB- agent associated anemia
amide -RSB- dimethoxybenz -LSB- agent associated anemia aplastic
amide -RSB- dimethoxybenz -LSB- agent associated anemia
remoxipride induce anemia aplastic
remoxipride induce anemia
remoxipride induce contribute anemia aplastic
remoxipride induce contribute anemia
remoxipride associated anemia contribute induce anemia aplastic
remoxipride associated anemia contribute induce anemia
remoxipride associated anemia aplastic
remoxipride associated anemia
benzene remoxipride induce anemia aplastic
benzene remoxipride induce anemia
benzene remoxipride induce contribute anemia aplastic
benzene remoxipride induce contribute anemia
bepridil induced Studies bradycardia
Bepridil induced bradycardia
maleate induced nephrotoxicity
maleate induced injury renal
maleate induced injury
maleate injection induced proteinuria
Maleate induced included injury renal
Maleate induced included injury
Maleate induced included included excretion glucosaminidase upregulation molecule kidney
Maleate induced included included excretion glucosaminidase upregulation molecule injury
Maleate induced included included excretion besides necrosis
maleate induced and nephropathy
Metronidazole induced encephalopathy
metronidazole intake encephalopathy
scopolamine Reversal amnesia
Scopolamine induced as amnesia
scopolamine amnesia
streptozotocin induced impairment memory
streptozotocin induced impairment
streptozotocin study induced impairment memory
streptozotocin study induced impairment
STZ streptozotocin study induced impairment memory
STZ streptozotocin study induced impairment
flutamide Administration impaired
flutamide Administration impaired memory the
flutamide Administration impaired memory
flutamide Administration impaired impairment memory
flutamide Administration impaired impairment
STZ improving attenuated impaired
STZ improving attenuated impaired memory the
STZ improving attenuated impaired memory
STZ improving attenuated impaired impairment memory
STZ improving attenuated impaired impairment
letrozole flutamide Administration impaired
letrozole flutamide Administration impaired memory the
letrozole flutamide Administration impaired memory
letrozole flutamide Administration impaired impairment memory
letrozole flutamide Administration impaired impairment
tamoxifen flutamide Administration impaired
tamoxifen flutamide Administration impaired memory the
tamoxifen flutamide Administration impaired memory
tamoxifen flutamide Administration impaired impairment memory
tamoxifen flutamide Administration impaired impairment
STZ ameliorates CONCLUSION impairment memory
STZ ameliorates CONCLUSION impairment
amitriptyline fluoxetine exacerbation paranoid
fluoxetine exacerbation paranoid
sotalol dl induced prolongation initiate pointes torsade
sotalol dl induced prolongation initiate pointes de
sotalol dl induced prolongation initiate pointes
sotalol dl induced prolongation initiate pointes TdP
sotalol dl induced prolongation QT
sotalol dl induced prolongation
Sotalol duration dl dependently prolongation leading QT
Sotalol duration dl dependently prolongation
sotalol dl EADs produced rabbits seen prolongation QT
sotalol dl EADs produced rabbits seen prolongation
sotalol propagation initiated episodes TdP
pentylenetetrazole investigates anxiety
caffeine induced anxiety
pentylenetetrazole caffeine induced anxiety
caffeine induced anxiety
caffeine nicotine anxiety
caffeine specific effect nicotine anxiety
d therapy neuropathy peripheral
d therapy neuropathy
4 therapy neuropathy peripheral
4 therapy neuropathy
T therapy neuropathy peripheral
T therapy neuropathy
NVP therapy associated rash
GTN increased Headache
GTN using headache
olanzapine risperidone difference index insulin
olanzapine risperidone difference index sensitivity
olanzapine risperidone difference was subjects received exhibiting resistance insulin
olanzapine risperidone difference was subjects received exhibiting resistance
olanzapine clozapine received subjects was difference index insulin
olanzapine clozapine received subjects was difference index sensitivity
olanzapine clozapine received exhibiting resistance insulin
olanzapine clozapine received exhibiting resistance
olanzapine risperidone 001 exhibiting received subjects was difference index insulin
olanzapine risperidone 001 exhibiting received subjects was difference index sensitivity
olanzapine risperidone 001 exhibiting resistance insulin
olanzapine risperidone 001 exhibiting resistance
clozapine risperidone difference index insulin
clozapine risperidone difference index sensitivity
clozapine risperidone difference was subjects received exhibiting resistance insulin
clozapine risperidone difference was subjects received exhibiting resistance
clozapine received subjects was difference index insulin
clozapine received subjects was difference index sensitivity
clozapine received exhibiting resistance insulin
clozapine received exhibiting resistance
clozapine risperidone risperidone treated subjects resistance exhibiting received subjects was difference index insulin
clozapine risperidone risperidone treated subjects resistance exhibiting received subjects was difference index sensitivity
clozapine risperidone risperidone treated subjects resistance insulin
clozapine risperidone risperidone treated subjects resistance
olanzapine risperidone 4 differed assessment resistance insulin
olanzapine risperidone 4 differed assessment resistance
olanzapine risperidone risperidone clozapine differed assessment resistance insulin
olanzapine risperidone risperidone clozapine differed assessment resistance
clozapine risperidone 4 differed assessment resistance insulin
clozapine risperidone 4 differed assessment resistance
clozapine differed assessment resistance insulin
clozapine differed assessment resistance
olanzapine clozapine nonobese CONCLUSIONS treated displayed resistance insulin
olanzapine clozapine nonobese CONCLUSIONS treated displayed resistance
clozapine nonobese CONCLUSIONS treated displayed resistance insulin
clozapine nonobese CONCLUSIONS treated displayed resistance
olanzapine clozapine taking Patients examined resistance insulin
olanzapine clozapine taking Patients examined resistance
clozapine taking Patients examined resistance insulin
clozapine taking Patients examined resistance
etomidate Prevention myoclonus
etomidate myoclonus
etomidate myoclonus
Heparin induced thrombocytopenia thromboembolism
heparin therapy effects thrombocytopenia thromboembolism
Heparin induced thrombocytopenia
heparin therapy effects thrombocytopenia
heparin therapy reactions osteoporosis
heparin reactions osteoporosis
heparin thrombocytopenia reactions osteoporosis
heparin therapy reactions eosinophilia
heparin reactions eosinophilia
heparin thrombocytopenia reactions eosinophilia
heparin therapy reactions skin
heparin therapy reactions reactions
heparin reactions skin
heparin reactions reactions
heparin thrombocytopenia reactions skin
heparin thrombocytopenia reactions reactions
heparin therapy effects discussed other thrombocytopenia alopecia
heparin reactions therapy effects discussed other thrombocytopenia alopecia
heparin thrombocytopenia reactions therapy effects discussed other thrombocytopenia alopecia
heparin therapy reactions thrombocytopenia
heparin therapy effects discussed other thrombocytopenia
heparin reactions thrombocytopenia
heparin reactions therapy effects discussed other thrombocytopenia
heparin thrombocytopenia
heparin thrombocytopenia reactions therapy effects discussed other thrombocytopenia
heparin therapy reactions allergic
heparin therapy reactions
heparin reactions allergic
heparin reactions
heparin thrombocytopenia reactions allergic
heparin thrombocytopenia reactions
All trans myositis
trans myositis
retinoic acid trans myositis
acid trans myositis
ATRA cases myositis
L bradykinesia February dyskinesias
DOPA February dyskinesias
propranolol loading induced failure heart
propranolol loading induced failure
Disoprivan occurred Pain
Disoprivan occurred Pain 001 < vs thrombophlebitis
phosphorus poisoning presentation Cholestatic
phosphorus Poisoning manifests hepatitis acute
phosphorus Poisoning manifests hepatitis
phosphorus Poisoning leading failure acute
phosphorus Poisoning leading failure liver
phosphorus Poisoning leading failure
phosphorus poisoning presented features cholestasis
phosphorus poisoning presented highlighting feature cholestasis
phosphorus hepatotoxicity feature highlighting presented features cholestasis
phosphorus hepatotoxicity feature cholestasis
spironolactone inhibitor converting caused hyperkalemia
ramipril doses considered cause hyperkalemia
spiranolactone doses considered cause hyperkalemia
aspirin taking prevention infarctions strokes
aspirin reviews SELECTION selected answer questions decrease events strokes
aspirin reviews SELECTION selected answer questions decrease events stroke
aspirin decrease events strokes
aspirin decrease events stroke
aspirin increase bleeding gastrointestinal
aspirin increase bleeding
aspirin use increases risk events gastrointestinal
aspirin use increases risk events bleeding
Aspirin reduces risk infarction men strokes
doxorubicin enhanced disturbances cardiac
doxorubicin enhanced disturbances
doxorubicin damage provoked damage heart
doxorubicin damage provoked damage
amitriptyline therapy Encephalopathy
amitriptyline therapy course developed encephalopathy
clarithromycin Rhabdomyolysis
simvastatin increment Rhabdomyolysis
clarithromycin dose occurred rhabdomyolysis
statin rhabdomyolysis
glycopyrrolate patients headache
glycopyrrolate patient headache
glycopyrrolate patients throat sore
glycopyrrolate patients throat
glycopyrrolate patient headache patients throat sore
glycopyrrolate patient headache patients throat
cocaine dysfunction cardiac
cocaine dysfunction
cocaine model function dysfunction cardiac
cocaine model function dysfunction
cocaine demonstrate extend due dysfunction cardiac
cocaine demonstrate extend due dysfunction
contrast Incidence nephropathy
contrast related factors frequency determine induced nephropathy
Contrast induced concern nephropathy
alcohol consumption depression
alcohol assessment examination measurement symptoms depression
alcohol assessment examination using self Scale Depression
alcohol consumption depression
alcohol consumption has association depression
isoproterenol decreased induced tachycardia
isoproterenol decreased induced exercise induced tachycardia
rifampin therapy failure hemolysis acute
rifampin therapy failure renal
rifampin therapy failure
rifampin therapy failure hemolysis
rifampin therapy failure acute
rifampin therapy failure renal
rifampin therapy failure
rifampin therapy failure leading hemolysis
rifampin failure hemolysis acute
rifampin failure renal
rifampin failure
rifampin failure hemolysis
oestrogen Long increased risk disease stroke gallbladder
oestrogen Long increased risk disease
oestrogen Long increased risk disease stroke
trimethaphan induced accompanied / tachycardia
trimethaphan induced accompanied hypotension
carbamazepine treated anemia aplastic
carbamazepine treated anemia
carbamazepine due anemia aplastic
carbamazepine due anemia
cyclosporin A tablets Long hypertension
A tablets Long hypertension
cyclosporin course hypertension
A therapy treated cyclosporin course hypertension
cyclosporin therapy exhibited state hypertensive
A therapy exhibited state hypertensive
cyclosporin A therapy events included 9 development hyperplasia gingival
cyclosporin A therapy events included 9 development hyperplasia
A therapy events included 9 development hyperplasia gingival
A therapy events included 9 development hyperplasia
nifedipine A therapy events included 9 development hyperplasia gingival
nifedipine A therapy events included 9 development hyperplasia
cyclosporin A treatment sustained monitored hyperplasia gingival
cyclosporin A treatment sustained monitored hyperplasia
A treatment sustained monitored hyperplasia gingival
A treatment sustained monitored hyperplasia
cyclosporin A treatment sustained useful patients hypertensive
A treatment sustained useful patients hypertensive
nifedipine useful sustained monitored hyperplasia gingival
nifedipine useful sustained monitored hyperplasia
piperacillin tazobactam doses seizure given report receiving dialysis developed speech confusion
/ tazobactam doses seizure given report receiving dialysis developed speech confusion
tazobactam doses seizure given report receiving dialysis developed speech confusion
piperacillin tazobactam doses seizure given report receiving dialysis developed speech episodes tonic
piperacillin tazobactam doses seizure clonic
piperacillin tazobactam doses seizure
/ tazobactam doses seizure given report receiving dialysis developed speech episodes tonic
/ tazobactam doses seizure clonic
/ tazobactam doses seizure
tazobactam doses seizure given report receiving dialysis developed speech episodes tonic
tazobactam doses seizure clonic
tazobactam doses seizure
piperacillin tazobactam doses seizure GTCS
/ tazobactam doses seizure GTCS
tazobactam doses seizure GTCS
piperacillin tazobactam doses seizure given report receiving dialysis developed speech tremor
/ tazobactam doses seizure given report receiving dialysis developed speech tremor
tazobactam doses seizure given report receiving dialysis developed speech tremor
piperacillin tazobactam dose recurred episode GTCS
/ tazobactam dose recurred episode GTCS
tazobactam dose recurred episode GTCS
gentamicin induced nephritis tubulointerstitial
gentamicin induced nephritis
gentamicin induced nephritis tubulointerstitial
gentamicin induced nephritis
sodium nitroprusside trimetaphan hypotension
nitroprusside trimetaphan hypotension
SNP nitroprusside trimetaphan hypotension
trimetaphan hypotension
TMP trimetaphan hypotension
nitroprusside hypotension used confirm data flow hypotension
nitroprusside hypotension
nitroprusside hypotension used confirm data flow hypotension effects Regarding mean hypotension
trimetaphan hypotension mean Regarding effects hypotension
trimetaphan hypotension mean Regarding effects hypotension flow data confirm used hypotension
trimetaphan hypotension
SNP hypotension
epinephrine clentiazem effects induced cardiomyopathy
Amiodarone induced pointes torsade
Amiodarone induced pointes de
Amiodarone induced pointes
amiodarone therapy associated pointes case development torsade
amiodarone therapy associated pointes case de
amiodarone therapy associated pointes
amiodarone therapy associated pointes TdP
amiodarone therapy absence induce TdP
xylometazoline clonidine effect effect effect cataleptic
codeine morphine induced analgesia effect effect effect cataleptic
codine morphine effect cataleptic
naphazoline clonidine effect effect effect cataleptic
clonidine effect effect effect cataleptic
fentanyl morphine induced analgesia effect effect effect cataleptic
fentanyl morphine effect cataleptic
morphine induced analgesia effect effect effect cataleptic
morphine effect cataleptic
fentanyl morphine induced catalepsy
morphine induced catalepsy
xylometazoline naphazoline decreased increased catalepsy
Codeine increased catalepsy
naphazoline decreased increased catalepsy
clonidine increased catalepsy
methamphetamine abuse associated brain deficits structural
methamphetamine abuse associated brain deficits
methamphetamine abuse associated brain in
methamphetamine abuse associated brain the
methamphetamine abuse associated brain human
methamphetamine abuse associated brain
MA abuse associated brain deficits structural
MA abuse associated brain deficits
MA abuse associated brain in
MA abuse associated brain the
MA abuse associated brain human
MA abuse associated brain
MA used subjects map abnormalities
MA used subjects map cortex in
MA used subjects map cortex the
MA used subjects map cortex
MA used subjects map cortex hippocampus
MA used subjects map cortex matter white
MA used subjects map cortex matter
MA used subjects map cortex and
MA used subjects map cortex ventricles
methamphetamine abuse causes pattern contributes performance impaired
methamphetamine abuse causes pattern contributes performance memory
methamphetamine abuse causes pattern contributes performance
MA abuse symptoms help providing targets injury brain
MA abuse symptoms help providing targets injury
Ozone Associations Concentrations Parkinson
Ozone Associations Concentrations Parkinson '
Ozone Associations Disease s
Ozone Associations Disease
particulate matter disease Parkinson
particulate matter disease Parkinson '
particulate matter disease s
particulate matter disease
matter disease Parkinson
matter disease Parkinson '
matter disease s
matter disease
ozone matter disease Parkinson
ozone matter disease Parkinson '
ozone matter disease s
ozone matter disease
particulate matter 0 odds ozone observed associations disease Parkinson
particulate matter 0 odds ozone observed associations disease Parkinson '
particulate matter 0 odds ozone observed associations disease s
particulate matter 0 odds ozone observed associations disease
matter 0 odds ozone observed associations disease Parkinson
matter 0 odds ozone observed associations disease Parkinson '
matter 0 odds ozone observed associations disease s
matter 0 odds ozone observed associations disease
ozone observed associations disease Parkinson
ozone observed associations disease Parkinson '
ozone observed associations disease s
ozone observed associations disease
ouabain activity tachycardia ventricular
ouabain activity tachycardia
strophanthidin activity displayed sodium arrhythmias
Citalopram Terfenadine blockers reported cause Pointes Torsade
Citalopram Terfenadine blockers reported cause Pointes de
Citalopram Terfenadine blockers reported cause Pointes
Citalopram Terfenadine blockers reported cause Pointes TdP
Terfenadine blockers reported cause Pointes Torsade
Terfenadine blockers reported cause Pointes de
Terfenadine blockers reported cause Pointes
Terfenadine blockers reported cause Pointes TdP
pilocarpine induced epilepticus status
pilocarpine induced epilepticus
pilocarpine injection induced epilepticus status
pilocarpine injection induced epilepticus
pilocarpine injection induced epilepticus SE
pilocarpine injection induced SE
pilocarpine regulated show induced SE
fluoxetine treatment Delirium
fluoxetine concentration hyperkinetic
fluoxetine desmethylfluoxetine concentration hyperkinetic
fluoxetine concentration delirium
fluoxetine desmethylfluoxetine concentration delirium
L induced changes spasm
norepinephrine L induced changes spasm
ecstasy observations line increases anxiety depression
Mefenamic acid induced failure neutropenia
acid induced failure neutropenia
Mefenamic acid induced failure neutropenia renal
Mefenamic acid induced failure
acid induced failure neutropenia renal
acid induced failure
mefenamic acid neutropenia
acid neutropenia
mefenamic acid failure renal
mefenamic acid failure
acid failure renal
acid failure
cocaine patients associated pain chest
cocaine patients associated pain
cocaine presenting admitted pain chest
cocaine presenting admitted pain
cocaine efficacious associated pain chest
cocaine efficacious associated pain
cocaine patients pain chest
cocaine patients pain
cocaine patients total RESULTS evaluated pain chest
cocaine patients total RESULTS evaluated pain
cocaine result discharged patients cocaine associated pain chest
cocaine result discharged patients cocaine associated pain
cocaine associated pain chest
cocaine associated pain
cocaine ischemia myocardial
cocaine ischemia
cocaine patients discharged result cocaine ischemia myocardial
cocaine patients discharged result cocaine ischemia
morphine administration achieved OIH
tetracycline induced liver Fatty
tetracycline induced liver
tetracycline induced liver fatty
tetracycline induced liver
tetracycline accounted liver fatty
tetracycline accounted liver
cyclophosphamide investigations lesions
cyclophosphamide investigations lesions bladder of
cyclophosphamide investigations lesions bladder the
cyclophosphamide investigations lesions bladder urinary
cyclophosphamide investigations lesions bladder
cocaine use alcohol pallidus case 31 man ischemia
cocaine use alcohol pallidus case 31 man ischemia globus of
cocaine use alcohol pallidus case 31 man ischemia globus the
cocaine use alcohol pallidus case 31 man ischemia globus
cocaine use alcohol pallidus
heroin associated infarctions globus
heroin associated infarctions pallidus
heroin associated infarctions
heroin use reported infarcts basal
heroin use reported infarcts ganglia
heroin use reported infarcts
5 infusion FU occurred pain block right
5 infusion FU occurred pain block bundle
5 infusion FU occurred pain block branch
5 infusion FU occurred pain block
FU occurred pain block right
FU occurred pain block bundle
FU occurred pain block branch
FU occurred pain block
5 infusion FU occurred pain precordial
5 infusion FU occurred pain
FU occurred pain precordial
FU occurred pain
5 discontinuation disappeared pain precordial
5 discontinuation disappeared pain
FU discontinuation disappeared pain precordial
FU discontinuation disappeared pain
5 due considered pain precordial
5 due considered pain
FU 5 due considered pain precordial
FU 5 due considered pain
5 administration induced 5 due considered pain precordial
5 administration induced 5 due considered pain
FU abandoned considered pain precordial
FU abandoned considered pain
isoproterenol hypertrophy cardiac
isoproterenol hypertrophy
risperidone administration developed syndrome malignant neuroleptic
risperidone administration developed syndrome malignant
risperidone administration developed syndrome
risperidone administration developed syndrome NMS
levomepromazine risperidone administration developed syndrome malignant neuroleptic
levomepromazine risperidone administration developed syndrome malignant
levomepromazine risperidone administration developed syndrome
levomepromazine risperidone administration developed syndrome NMS
cocaine exposure infants preterm
cocaine exposure infants
cocaine exposure linked hemorrhage formation cysts
cocaine exposure increases incidence cysts infants preterm
cocaine exposure increases incidence cysts infants
cocaine prenatally exposed incidence formation infants preterm
cocaine prenatally exposed incidence formation infants
Tacrolimus seizure
TAC level gender included factors associated seizures
TAC level factor associated seizures
TAC level factor contributed seizures
TAC factors serum PELD seizures
oestrogen therapy associated hyperplasia
oestrogen therapy problems difficulty hyperplasia
cocaine patients Clinical associated infarction myocardial
cocaine patients Clinical associated infarction
cocaine setting evaluate induced infarction myocardial
cocaine setting evaluate induced infarction
cocaine setting evaluate induced infarction MI
cocaine Patients PARTICIPANTS associated MI
cocaine setting lidocaine associated MI
cocaine toxicity enhance associated MI
cocaine patients enhance associated MI
Ethambutol optic
Ethambutol neuropathy
ethambutol optic
ethambutol neuropathy
ethambutol treated developed neuropathy optic
ethambutol treated developed neuropathy
ethambutol therapy starting had neuropathy optic
ethambutol therapy starting had neuropathy
ethambutol therapy patients considered recognition neuropathy optic
ethambutol therapy patients considered recognition neuropathy
cocaine evaluation assess study associated pain chest
cocaine evaluation assess study associated pain
cocaine use setting pain Chest
cocaine use setting pain
cocaine use setting dobutamine administration concern conducted study associated pain chest
cocaine use setting dobutamine administration concern conducted study associated pain
cocaine assess study associated pain chest
cocaine assess study associated pain
cocaine used hours preceding onset pain chest
cocaine used hours preceding onset pain
cocaine patients pain chest
cocaine patients pain
dobutamine treatment pointes de Torsade
dobutamine treatment pointes de
dobutamine treatment pointes
dobutamine dose cycle tachycardia torsade
dobutamine dose cycle tachycardia de
dobutamine dose cycle tachycardia pointes
dobutamine tachycardia torsade
dobutamine tachycardia torsade de
dobutamine tachycardia pointes
Amiodarone risk bradyarrhythmia
amiodarone use increases risk bradyarrhythmia
amiodarone therapy bradyarrhythmia
amiodarone use increases risk bradyarrhythmia
bupivacaine production effects expression increases pain postoperative
bupivacaine production effects expression increases pain
Penicillin anaphylaxis
penicillin anaphylaxis
penicillin anaphylaxis case described reviewed terminology treatment anaphylaxis
penicillin anaphylaxis
cyclophosphamide neurons induced cystitis
cyclophosphamide induced inflammation bladder
cyclophosphamide induced inflammation
CYP cyclophosphamide induced inflammation bladder
CYP cyclophosphamide induced inflammation
CYP induced increased cystitis
CYP increased immunoreactive number cystitis
CYP demonstrated reaction real induced cystitis
isoproterenol severity exercise Effects infarction myocardial
isoproterenol severity exercise Effects infarction
isoproterenol severity infarction myocardial
isoproterenol severity infarction
flecainide concentrations patient Delirium
paroxetine interaction role Delirium
flecainide case describe induced delirium
paroxetine interaction associated delirium
Flecainide agents cause delirium
flecainide delirium
flecainide reports paroxetine flecainide delirium
paroxetine flecainide delirium
flecainide cause delirium
flecainide interaction indicates cause delirium
paroxetine flecainide interaction indicates cause delirium
flecainide concentrations cause delirium
trimethoprim alone SMZ prescribed persons similar risk disease liver
trimethoprim alone SMZ prescribed persons similar risk disease
TMP SMZ prescribed persons similar risk disease liver
TMP SMZ prescribed persons similar risk disease
SMZ prescribed persons similar risk disease liver
SMZ prescribed persons similar risk disease
TMP exposed disorders experienced SMZ SMZ seven Stevens
TMP exposed disorders experienced SMZ SMZ seven Stevens Johnson
TMP exposed disorders experienced SMZ SMZ seven Stevens Johnson syndrome
SMZ seven Stevens
SMZ seven Stevens Johnson
SMZ seven Stevens Johnson syndrome
TMP exposed Johnson Stevens
TMP exposed Johnson
TMP exposed Johnson syndrome
SMZ SMZ seven Stevens
SMZ SMZ seven Stevens Johnson
SMZ SMZ seven Stevens Johnson syndrome
cephalexin took patient occurred case necrolysis toxic
cephalexin took patient occurred case necrolysis epidermal
cephalexin took patient occurred case necrolysis
BCNU model cortex induced dysplasia cortical
BCNU model cortex induced dysplasia
carmustine induced cerebellum evaluate investigate BCNU induced dysplasia cortical
carmustine induced cerebellum evaluate investigate BCNU induced dysplasia
1 -LSB- carmustine induced cerebellum evaluate investigate BCNU induced dysplasia cortical
1 -LSB- carmustine induced cerebellum evaluate investigate BCNU induced dysplasia
3 -LSB- carmustine induced cerebellum evaluate investigate BCNU induced dysplasia cortical
3 -LSB- carmustine induced cerebellum evaluate investigate BCNU induced dysplasia
bis carmustine induced cerebellum evaluate investigate BCNU induced dysplasia cortical
bis carmustine induced cerebellum evaluate investigate BCNU induced dysplasia
2 bis carmustine induced cerebellum evaluate investigate BCNU induced dysplasia cortical
2 bis carmustine induced cerebellum evaluate investigate BCNU induced dysplasia
chloroethyl 2 bis carmustine induced cerebellum evaluate investigate BCNU induced dysplasia cortical
chloroethyl 2 bis carmustine induced cerebellum evaluate investigate BCNU induced dysplasia
1 carmustine induced cerebellum evaluate investigate BCNU induced dysplasia cortical
1 carmustine induced cerebellum evaluate investigate BCNU induced dysplasia
nitrosoure -RSB- carmustine induced cerebellum evaluate investigate BCNU induced dysplasia cortical
nitrosoure -RSB- carmustine induced cerebellum evaluate investigate BCNU induced dysplasia
BCNU evaluate investigate BCNU induced dysplasia cortical
BCNU evaluate investigate BCNU induced dysplasia
BCNU induced dysplasia cortical
BCNU induced dysplasia
BCNU noted group cortical
BCNU noted group dysplasia
Linezolid induced neuropathy optic
Linezolid induced neuropathy
veralipride use Worsening Parkinsonism
veralipride symptoms therapy marked shown patient disease Parkinson
veralipride symptoms therapy marked shown patient disease Parkinson '
veralipride symptoms therapy marked shown patient disease s
veralipride symptoms therapy marked shown patient disease
levodopa characterize was induced dyskinesia
levodopa dose basis explained function swallowing performed patients dyskinetic
imipramine induced Hypertension
Imipramine given occurrence hypertension
Imipramine discontinuation diagnosis elevation had believe caused hypertension
Doxorubicin induced monitored cardiotoxicity
doxorubicin induced cardiotoxicity
doxorubicin protectors testing allows model result induced cardiotoxicity
bupivacaine AD determining concentration bupivacaine caused myocyte become arrhythmic
bupivacaine caused myocyte become arrhythmic
progesterone exposure effect determined determining concentration bupivacaine caused myocyte become arrhythmic
bupivacaine arrhythmia
doxorubicin cardiotoxicity
doxorubicin cardiotoxicity
DOX doxorubicin cardiotoxicity
DOX received animals observed deaths related cardiotoxicity
DOX received animals observed revealed heart consistent cardiotoxicity
DOX copolymer mixture DOX received animals observed deaths related cardiotoxicity
DOX copolymer mixture DOX received animals observed revealed heart consistent cardiotoxicity
DOX consistent heart revealed observed deaths related cardiotoxicity
DOX consistent cardiotoxicity
Gentamicin OAT AQP ATPase K induced Nephropathy
gentamicin transporters regulation is induced nephropathy
Gentamicin related nephropathy
amino compounds effect Hyperglycemic
amino derivatives amounts feeding resulted hyperglycemia
Levodopa induced dyskinesias ocular
Levodopa induced dyskinesias
Levodopa induced uncommon dyskinesias ocular
Levodopa induced uncommon dyskinesias
levodopa effect report hypothesize induce dyskinesias ocular
levodopa effect report hypothesize induce dyskinesias
levodopa appearance needed hypothesize induce dyskinesias ocular
levodopa appearance needed hypothesize induce dyskinesias
tiapride tetrabenazine therapy induced syndrome Neuroleptic
tiapride tetrabenazine therapy induced syndrome malignant
tiapride tetrabenazine therapy induced syndrome
tetrabenazine therapy induced syndrome Neuroleptic
tetrabenazine therapy induced syndrome malignant
tetrabenazine therapy induced syndrome
tiapride therapy initiation occurred case 81 woman syndrome neuroleptic
tiapride therapy initiation occurred case 81 woman syndrome malignant
tiapride therapy initiation occurred case 81 woman syndrome
tetrabenazine tiapride therapy initiation occurred case 81 woman syndrome neuroleptic
tetrabenazine tiapride therapy initiation occurred case 81 woman syndrome malignant
tetrabenazine tiapride therapy initiation occurred case 81 woman syndrome
tiapride tetrabenazine therapy due syndrome neuroleptic
tiapride tetrabenazine therapy due syndrome malignant
tiapride tetrabenazine therapy due syndrome
tetrabenazine therapy due syndrome neuroleptic
tetrabenazine therapy due syndrome malignant
tetrabenazine therapy due syndrome
vancomycin pathogenesis suggesting induced nephrotoxicity
vancomycin examine investigate role erdosteine antioxidant tissue VCM induced impairment renal
vancomycin examine investigate role erdosteine antioxidant tissue VCM induced impairment
VCM vancomycin examine investigate role erdosteine antioxidant tissue VCM induced impairment renal
VCM vancomycin examine investigate role erdosteine antioxidant tissue VCM induced impairment
VCM induced impairment renal
VCM induced impairment
VCM administration increased excretion NAG marker injury renal
VCM administration increased excretion NAG marker injury tubular
VCM administration increased excretion NAG marker injury
VCM showed induced nephrotoxicity
VCM role plays concluded reduces induced nephrotoxicity
VCM role plays concluded reduces VCM induced damage kidney
VCM role plays concluded reduces VCM induced damage
VCM reduces induced nephrotoxicity
VCM induced damage kidney
VCM induced damage
halothane anaesthetized cats induced arrhythmias cardiac
halothane anaesthetized cats induced arrhythmias
adrenaline induced arrhythmias cardiac
adrenaline induced arrhythmias
adrenaline dose increasing surmountable Blockade arrhythmias
ouabain caused tachycardia ventricular
ouabain caused tachycardia
Heparin induced thrombocytopenia
Heparin induced remains thrombocytopenia
Heparin induced remains thrombocytopenia HIT
heparin exposure occurs suspected acknowledged predilection thrombosis
heparin exposure occurs thrombosis
heparin exposure occurs suspected acknowledged HIT
heparin exposure cessation mandates treatment HIT
heparin patients history HIT
heparin remains one most used potential HIT
heparin exposure used potential HIT
heparin initiated practiced remains one most used potential HIT
busulfan course days developed seizures
everolimus treated amyloidosis AL
everolimus treated amyloidosis
everolimus treated diagnosis proteinuria
everolimus tacrolimus developed amyloidosis
everolimus tacrolimus developed proteinuria
isoproterenol 76 induced hypertrophy heart
isoproterenol 76 induced hypertrophy
isoproterenol model hypertrophy heart
isoproterenol model hypertrophy
isoproterenol prevent producing hypertrophy heart
isoproterenol prevent producing hypertrophy
lidocaine group hypotension
lidocaine received nine hypotension
lidocaine had asystole died patients hypotension
dexmedetomidine receive prevalence occur hypotension
propofol dexmedetomidine receive prevalence occur hypotension bradycardia
dexmedetomidine receive prevalence occur hypotension bradycardia
propofol dexmedetomidine receive prevalence occur hypotension
pilocarpine induced epilepticus status
pilocarpine induced epilepticus
pilocarpine induced epilepticus status
pilocarpine induced epilepticus
pilocarpine model epilepsy temporal
pilocarpine model epilepsy lobe
pilocarpine model epilepsy
methylprednisolone therapy dose Bradycardia
verapamil therapy rhythms junctional Accelerated
verapamil therapy rhythms junctional
verapamil therapy rhythms
verapamil receiving patients examined frequency dissociation rhythms accelerated
verapamil receiving patients examined frequency dissociation rhythms junctional
verapamil receiving patients examined frequency dissociation rhythms
streptozotocin development induced nephropathy diabetic
streptozotocin development induced nephropathy
STZ nephropathy diabetic
STZ nephropathy
STZ induced nephropathy diabetic
STZ induced nephropathy
droperidol due anxiety
droperidol induced disturbance psychological
droperidol induced disturbance
calcium blockers tolerated effects headache edema anorexia
channel blockers tolerated effects headache edema anorexia
blockers tolerated effects headache edema anorexia
calcium blockers tolerated effects headache edema dizziness
channel blockers tolerated effects headache edema dizziness
blockers tolerated effects headache edema dizziness
calcium blockers tolerated effects headache
channel blockers tolerated effects headache
blockers tolerated effects headache
calcium blockers tolerated effects headache edema
channel blockers tolerated effects headache edema
blockers tolerated effects headache edema
calcium blockers tolerated effects headache edema nausea
channel blockers tolerated effects headache edema nausea
blockers tolerated effects headache edema nausea
calcium blockers tolerated effects headache flushing
channel blockers tolerated effects headache flushing
blockers tolerated effects headache flushing
diphenylhydantoin taking patient Pure
diphenylhydantoin taking patient Pure aplasia red
diphenylhydantoin taking patient Pure aplasia cell
diphenylhydantoin taking patient Pure aplasia
diphenylhydantoin taking patient Pure aplasia lymphadenopathy
diphenylhydantoin taking patient Pure aplasia dermatitis toxic
diphenylhydantoin taking patient Pure aplasia dermatitis
diphenylhydantoin taking patient developed rash aplasia pure
diphenylhydantoin taking patient developed rash aplasia red
diphenylhydantoin taking patient developed rash aplasia cell
diphenylhydantoin taking patient developed rash aplasia
diphenylhydantoin taking patient developed rash lymphadenopathy
diphenylhydantoin treatment complication known benign lymphadenopathy
diphenylhydantoin medication associated aplasia Pure
diphenylhydantoin medication associated aplasia red
diphenylhydantoin medication associated aplasia cell
diphenylhydantoin medication associated aplasia
diphenylhydantoin ingestion relation suggestive aplasia lymphadenopathy pure
diphenylhydantoin ingestion relation suggestive aplasia red
diphenylhydantoin ingestion relation suggestive aplasia cell
diphenylhydantoin ingestion relation suggestive aplasia
diphenylhydantoin ingestion relation suggestive aplasia lymphadenopathy
cyclophosphamide receptor induced cystitis
cyclophosphamide NK explore is study purpose PURPOSE cystitis
CYP cyclophosphamide NK explore is study purpose PURPOSE cystitis
CYP administration behaviors pain
Cyclophosphamide treatment increased behaviors pain
CYP CONCLUSIONS induced cystitis
methamphetamine dose induces behaviour depressive
Methamphetamine triggers leads states symptoms depressive
Methamphetamine triggers leads states symptoms
METH Methamphetamine triggers leads states symptoms depressive
METH Methamphetamine triggers leads states symptoms
METH abuse system disruption leads states symptoms depressive
METH abuse system disruption leads states symptoms
METH dosage causes long phenotype depressive
METH dose periods assessed term depressive
METH induced profile accompanied depressive
METH dose induces demonstrate mice depressive
streptozotocin inflammation paw carrageenan induced neuropathy diabetic
streptozotocin inflammation paw carrageenan induced neuropathy
STZ inflammation paw carrageenan induced neuropathy diabetic
STZ inflammation paw carrageenan induced neuropathy
carrageenan paw inflammation
STZ 1 14 doses calculated cause 7 reversal hyperalgesia
carrageenan model 1 83 doses calculated cause 7 reversal hyperalgesia
CPA therapy caused mediated % coronary
CPA therapy caused mediated % coronary arteriosclerosis
CPA therapy caused mediated % coronary A known effect hyperglyceridemic
CPA therapy caused mediated % coronary A known effect
lithium drugs used consider asterixis
clozapine lithium drugs used consider asterixis
pilocarpine timolol drops associated bradycardia
timolol drops associated bradycardia hypotension
pilocarpine timolol drops associated bradycardia hypotension
timolol drops associated bradycardia
pilocarpine nitrate treated man developed bradycardia
nitrate treated man developed bradycardia
timolol drops nitrate treated man developed became hypotensive
maleate drops nitrate treated man developed became hypotensive
pilocarpine nitrate treated man developed became hypotensive
nitrate treated man developed became hypotensive
timolol drops nitrate treated man developed bradycardia
maleate drops nitrate treated man developed bradycardia
methotrexate therapy failure Acute
methotrexate therapy failure renal
methotrexate therapy failure
MTX therapy HD report case failure acute
MTX therapy HD report case failure renal
MTX therapy HD report case failure
MTX therapy caused failure acute
MTX therapy caused failure renal
MTX therapy caused failure
olanzapine treated had gain weight
olanzapine treated had gain
olanzapine treated patients treatment somnolence
haloperidol induced Hyperprolactinemia
haloperidol month hyperprolactinemia
carbachol potentiated inhibited enlargement
carbachol potentiated inhibited enlargement pulse of
carbachol potentiated inhibited enlargement pulse
carbachol potentiated inhibited pressure
desmethylimipramine mg i inhibited enlargement
desmethylimipramine mg i inhibited enlargement pulse of
desmethylimipramine mg i inhibited enlargement pulse
desmethylimipramine mg i inhibited pressure
carbachol potentiated inhibited pressure tachycardia
cyclosporine Conversion induced nephropathy
cyclosporin A conversion Protocols used prevent CsA induced nephropathy
A conversion Protocols used prevent CsA induced nephropathy
CsA A conversion Protocols used prevent CsA induced nephropathy
CsA induced nephropathy
SRL treated rats presented proteinuria
CsA treatment presented lesions kidney
CsA treatment presented lesions
CsA exposure aggravated damage renal
CsA exposure aggravated damage
CsA induced evolution renal
CsA induced evolution damage
CsA replacement biomarker seems induced evolution renal
CsA replacement biomarker seems induced evolution damage
Amiodarone reported cause hepatotoxicity
Amiodarone induced hepatomegaly
amiodarone effects dependent indicated hepatomegaly
amiodarone effects hepatotoxic
amiodarone effects information provide indicate protects amiodarone induced hepatotoxicity
amiodarone protects indicate provide information effects hepatotoxic
amiodarone induced hepatotoxicity
cocaine users recognition fear Impaired
cocaine users recognition fear
cocaine users recognition
cocaine effects explained manifested deficit
cocaine effects explained manifested deficit accuracy in
cocaine effects explained manifested deficit accuracy fear
cocaine effects explained manifested deficit accuracy recognition
apomorphine dexamphetamine trazodone effect METHODS induced catalepsy
apomorphine haloperidol behavior induced catalepsy
haloperidol behavior induced catalepsy
apomorphine antagonize induce catalepsy
apomorphine antagonize induce RESULTS induced catalepsy
apomorphine stereotypy apomorphine antagonize induce catalepsy
apomorphine stereotypy apomorphine antagonize induce RESULTS induced catalepsy
haloperidol catalepsy
apomorphine stereotypies antagonized induced catalepsy
haloperidol catalepsy
dexamethasone mice Treatment led elevation pressure degeneration axonal
dexamethasone mice Treatment led elevation pressure degeneration
dexamethasone mice Treatment led resembling glucocorticoid glaucoma
dexamethasone hypertension ocular
dexamethasone hypertension
Dexamethasone induced reduced prevented dexamethasone hypertension ocular
Dexamethasone induced reduced prevented dexamethasone hypertension
dexamethasone hypertension ocular
dexamethasone hypertension
dexamethasone prevented phenylbutyrate TM induced hypertension ocular
dexamethasone prevented phenylbutyrate TM induced hypertension
disulfiram induced hepatitis Toxic
disulfiram induced hepatitis
disulfiram treated woman non observed damage toxic
disulfiram treated woman non observed damage liver
disulfiram treated woman non observed damage
Levodopa therapy lead outcomes fluctuations hallucinations visual
Levodopa therapy lead outcomes fluctuations hallucinations
Levodopa therapy lead outcomes fluctuations dyskinesia
doxorubicin cardiomyopathy
DOX doxorubicin cardiomyopathy
Trimethoprim induced anemia hemolytic
Trimethoprim induced anemia
nicergoline due nephritis interstitial
nicergoline due nephritis
Sermion nicergoline due nephritis interstitial
Sermion nicergoline due nephritis
nicergoline nephritis interstitial
nicergoline nephritis
nicergoline nephritis AIN
Sermion nephritis interstitial
Sermion nephritis
Sermion nephritis AIN
nicergoline associated AIN
acetaminophen failure acute
acetaminophen failure liver
acetaminophen failure
Acetaminophen BACKGROUND cause hepatotoxicity
Acetaminophen BACKGROUND cause failure acute
Acetaminophen BACKGROUND cause failure liver
Acetaminophen BACKGROUND cause failure
Acetaminophen BACKGROUND cause failure ALF
acetaminophen 2004 undergone patients outcomes severity ALF
acetaminophen 2004 undergone patients outcomes severity acetaminophen ALF
acetaminophen severity ALF
acetaminophen ALF
Acetaminophen undergoing patients ALF
acetaminophen had patients ALF
acetaminophen had had LT non 01 0 ALF
acetaminophen 01 non LT had had patients ALF
acetaminophen 01 0 ALF
acetaminophen ALF
acetaminophen ALF years ALF
acetaminophen non years ALF
acetaminophen non years ALF
acetaminophen induced patients ALF
acetaminophen transplanted comparable ALF
acetaminophen transplanted comparable transplanted ALF
acetaminophen transplanted comparable ALF
acetaminophen transplanted ALF
d treated patients pointes efficacy incidence pointes torsades
d treated patients pointes efficacy incidence pointes de
d treated patients pointes efficacy incidence pointes
l d treated patients pointes efficacy incidence pointes torsades
l d treated patients pointes efficacy incidence pointes de
l d treated patients pointes efficacy incidence pointes
sotalol study evaluated efficacy incidence pointes torsades
sotalol study evaluated efficacy incidence pointes de
sotalol study evaluated efficacy incidence pointes
d treated patients pointes efficacy factors torsades
d treated patients pointes efficacy de
d treated patients pointes
l d treated patients pointes efficacy factors torsades
l d treated patients pointes efficacy de
l d treated patients pointes
sotalol study evaluated efficacy factors torsades
sotalol study evaluated efficacy de
sotalol study evaluated efficacy pointes
d treatment pointes torsades
d treatment pointes torsades de
d treatment pointes
l torsades
l torsades de
l torsades pointes
sotalol torsades
sotalol torsades de
sotalol torsades pointes
d dose lower patients pointes torsades
d dose lower patients pointes de
d dose lower patients pointes
l d dose lower patients pointes torsades
l d dose lower patients pointes de
l d dose lower patients pointes
sotalol l d dose lower patients pointes torsades
sotalol l d dose lower patients pointes de
sotalol l d dose lower patients pointes
d treatment years had torsades
d treatment years had torsades de
d treatment years had torsades pointes
l d treatment years had torsades
l d treatment years had torsades de
l d treatment years had torsades pointes
sotalol l d treatment years had torsades
sotalol l d treatment years had torsades de
sotalol l d treatment years had torsades pointes
d doses occurred pointes Torsades
d doses occurred pointes de
d doses occurred pointes
l occurred pointes Torsades
l occurred pointes de
l occurred pointes
sotalol l occurred pointes Torsades
sotalol l occurred pointes de
sotalol l occurred pointes
d dose relation ECG changes identify risk pointes torsades
d dose relation ECG changes identify risk pointes de
d dose relation ECG changes identify risk pointes
l changes identify risk pointes torsades
l changes identify risk pointes de
l changes identify risk pointes
sotalol identify risk pointes torsades
sotalol identify risk pointes de
sotalol identify risk pointes
d application parameters identify risk pointes torsades
d application parameters identify risk pointes de
d application parameters identify risk pointes
l d application parameters identify risk pointes torsades
l d application parameters identify risk pointes de
l d application parameters identify risk pointes
sotalol l d application parameters identify risk pointes torsades
sotalol l d application parameters identify risk pointes de
sotalol l d application parameters identify risk pointes
acetaminophen female year induced failure fulminant
acetaminophen female year induced failure liver
acetaminophen female year induced failure
acetaminophen female year induced AKI
clopidogrel associated hepatitis
clopidogrel case describe hepatitis
clopidogrel hepatotoxicity
clopidogrel prescribed injury hepatic
clopidogrel prescribed injury
steroid injection occurred woman presented sensation paresthesia
steroid injection occurred paresthesia
isotretinoin report anomalies anotia Taussig
isotretinoin report anomalies anotia malformation Bing
isotretinoin report anomalies anotia malformation
isotretinoin report anomalies anotia
isoproterenol induced hypertrophy cardiac
isoproterenol induced hypertrophy
Iso treatment induced LV
Iso treatment induced hypertrophy
nicotine Relationship seizures
nicotine relationship induced seizures
nicotine effects sensitive Mice had alpha bungarotoxin hippocampus mice seizure
quinine amblyopia
quinine sulfate use man blindness
sulfate use man blindness
quinine sulfate use man blindness response tonic
quinine sulfate use man blindness response pupillary
sulfate use man blindness response tonic
sulfate use man blindness response pupillary
quinine toxicity potentials supersensitivity denervation response tonic
quinine toxicity potentials supersensitivity denervation response pupillary
beclomethasone dipropionate developed candidiasis hoarseness
dipropionate developed candidiasis hoarseness
beclomethasone dipropionate developed candidiasis oral
beclomethasone dipropionate developed candidiasis
dipropionate developed candidiasis oral
dipropionate developed candidiasis
beclomethasone placed patients developed hoarseness
beclomethasone placed patients developed hoarseness thrush
beclomethasone restarted conclude challenged because patients develop re hoarseness
beclomethasone prednisone use increase risk developing hoarseness
methadone therapy male Rhabdomyolysis
heroin stroke Rhabdomyolysis
heroin presented rhabdomyolysis
methadone using Those CONCLUSION increase risk rhabdomyolysis
heroin methadone using Those CONCLUSION increase risk rhabdomyolysis
heroin rhabdomyolysis stroke
heroin abusers rhabdomyolysis stroke
heroin rhabdomyolysis
heroin abusers rhabdomyolysis
Tacrolimus ointment used indicate effective aggravated dermatitis rosacea
CY toxicity caused cystitis haemorrhagic
CY toxicity caused cystitis
CY ulcerous days appeared forms cystitis
procaterol effects asthmatic tremorgenic
Chinese pill use failure acute
Chinese pill use failure renal
Chinese pill use failure
herbal pill use failure acute
herbal pill use failure renal
herbal pill use failure
diclofenac intake aggravated injury renal
diclofenac intake aggravated injury
Methoxamine evoked caused rise a
Methoxamine evoked caused rise significant
Methoxamine evoked caused rise
Methoxamine evoked caused pressure in
Methoxamine evoked caused pressure systolic
Methoxamine evoked caused pressure blood
Methoxamine evoked caused pressure
isoproterenol placebo tachycardia
isoproterenol tachycardia
isoproterenol activates blocked activation results tachycardia
TNA dose hours had episode convulsions tonic
TNA dose hours had episode convulsions clonic
TNA dose hours had episode convulsions
crack cocaine smokers seroconversion HIV
crack cocaine smokers seroconversion
cocaine smokers seroconversion HIV
cocaine smokers seroconversion
crack cocaine smokers participants seroconversion HIV
crack cocaine smokers participants seroconversion
cocaine smokers participants seroconversion HIV
cocaine smokers participants seroconversion
crack cocaine Smoking found factor seroconversion HIV
crack cocaine Smoking found factor seroconversion
cocaine Smoking found factor seroconversion HIV
cocaine Smoking found factor seroconversion
ritodrin decreased amplitudes tremor
HCl infusion ritodrin decreased amplitudes tremor
fenoterol end infusion decreased amplitudes tremor
hydrobromide infusion decreased amplitudes tremor
succinylcholine administration dose rocuronium fasciculation myalgia
succinylcholine administration dose rocuronium fasciculation
Succinylcholine produces effects fasciculation myalgia
Succinylcholine produces effects fasciculation muscle
Succinylcholine produces effects fasciculation
succinylcholine prevent identified induced fasciculation myalgia
succinylcholine produced study identified induced fasciculation myalgia
succinylcholine prevent identified induced fasciculation
succinylcholine produced study identified induced fasciculation
succinylcholine kg received assessed assessed myalgia
succinylcholine kg received assessed incidence fasciculations
ribavirin Interferon produces anemia hemolytic
ribavirin Interferon produces anemia
Interferon produces anemia hemolytic
Interferon produces anemia
ifosfamide nephropathy
ifosfamide anti responsible damage renal
ifosfamide anti responsible damage
IFO ifosfamide anti responsible damage renal
IFO ifosfamide anti responsible damage
IFO therapy anti responsible damage renal
IFO therapy anti responsible damage
IFO prevent nephropathy
CTX treatment neutropenia frequency % effect Neutropenia
CTX treatment neutropenia
CCNU CTX treatment neutropenia frequency % effect Neutropenia
CCNU CTX treatment neutropenia
17 alpha shows associated cholestasis intrahepatic
17 alpha shows associated cholestasis
alpha shows associated cholestasis intrahepatic
alpha shows associated cholestasis
ethinylestradiol alpha shows associated cholestasis intrahepatic
ethinylestradiol alpha shows associated cholestasis
EE ethinylestradiol alpha shows associated cholestasis intrahepatic
EE ethinylestradiol alpha shows associated cholestasis
morphine CCK induced decreases amnesia
morphine hippocampus region induced decreases amnesia
Carbimazole ANCA
Carbimazole ANCA vasculitis positive
Carbimazole ANCA vasculitis
antithyroidmedications effect threatening life vasculitis antibody Antineutrophil
antithyroidmedications effect threatening life vasculitis antibody cytoplasmic
antithyroidmedications effect threatening life vasculitis antibody
antithyroidmedications effect threatening life vasculitis antibody ANCA
antithyroidmedications effect threatening life vasculitis associated
antithyroidmedications effect threatening life vasculitis
indomethacin misoprostol effect dose dysfunction renal
indomethacin misoprostol effect dose dysfunction
indomethacin induced dysfunction renal
indomethacin induced dysfunction
adenosine triphosphate induced effects hypotension
triphosphate induced effects hypotension
sodium nitroprusside triphosphate induced effects hypotension
nitroprusside triphosphate induced effects hypotension
Adenosine triphosphate administered induce hypotension
triphosphate administered induce hypotension
ATP triphosphate administered induce hypotension
sodium nitroprusside triphosphate administered induce hypotension
nitroprusside triphosphate administered induce hypotension
SNP nitroprusside triphosphate administered induce hypotension
ATP induced Hypotension
ATP stopped returned accompanied Hypotension
SNP decreases produced hypotension
Bisphenol A exposure increases anxiety
A exposure increases anxiety
BPA exposed mice increased indicated anxiety
BPA exposure increased anxiety
sulfadiazine nephrotoxicity acute
sulfadiazine nephrotoxicity
Sulfadiazine acute
Sulfadiazine acute reviving nephrotoxicity
sulfadiazine treatment developed showed calculi renal
sulfadiazine treatment developed showed calculi
helodermin produced hypotension
Helodermin produced hypotension
levcromakalim abolished glibenclamide attenuated Hypotension
acetylcholine duration shortened induced hypotension
acetylcholine duration shortened induced helodermin produced hypotension
ACh acetylcholine duration shortened induced hypotension
ACh acetylcholine duration shortened induced helodermin produced hypotension
helodermin induced hypotension
helodermin produced hypotension
helodermin suggest attributable hypotension
Streptozotocin induced impairment memory
Streptozotocin induced impairment
Streptozotocin activation role rats memory
Streptozotocin activation role rats impaired
STZ role rats memory
STZ role rats impaired
STZ administration days found deficit Memory
STZ administration days found deficit
STZ causes expression CD neuroinflammation
STZ impairment memory
STZ impairment
propranolol induced hypertension
pilocarpine animals epilepsy
Indomethacin hypotension
adrenaline Support hypertension
adrenaline infusion effect Support hypertension
adrenaline support hypothesis hypertension
levodopa prior neuropsychiatric evaluated time disability dyskinesia
levodopa increase induced fluctuations dyskinesia
levodopa therapy duration correlated increase induced fluctuations dyskinesia
tobramycin concentration duration related Azotemia
doxorubicin cardiomyopathy
Indomethacin typical cystitis interstitial
Indomethacin typical cystitis
Indomethacin epithelium mastocytosis
L reduced dyskinesias
DOPA dyskinesias
L development lesion dyskinesias
DOPA lesion dyskinesias
Contrast nephrotoxicity
medium nephrotoxicity
contrast medium induced dysfunction Renal
contrast medium induced dysfunction
medium induced dysfunction Renal
medium induced dysfunction
CM medium induced dysfunction Renal
CM medium induced dysfunction
CM effect nephrotoxic
CM administration induced damage renal
CM administration induced damage
all complications Thrombotic
trans complications Thrombotic
retinoic therapy trans complications Thrombotic
acid therapy trans complications Thrombotic
all treated occlusion due failure acute
all treated occlusion due failure renal
all treated occlusion due failure
trans all treated occlusion due failure acute
trans all treated occlusion due failure renal
trans all treated occlusion due failure
retinoic acid all treated occlusion due failure acute
retinoic acid all treated occlusion due failure renal
retinoic acid all treated occlusion due failure
acid all treated occlusion due failure acute
acid all treated occlusion due failure renal
acid all treated occlusion due failure
ATRA acid all treated occlusion due failure acute
ATRA acid all treated occlusion due failure renal
ATRA acid all treated occlusion due failure
ATRA treated patient report case failure acute
ATRA treated patient report case failure renal
ATRA treated patient report case failure
aminophylline infusions received onset seizures
lithium therapy leading hyperparathyroidism
lithium treated patient had hypercalcemia
lithium % IMPLICATIONS treated become hypercalcemic
methamphetamine psychosis
methamphetamine factors psychosis
methamphetamine risk determine was study objective OBJECTIVE psychosis
methamphetamine dependence patients psychosis
methamphetamine morbidity association induced studied psychosis
methamphetamine diagnosis Patients based interviewed using Interview disorders methamphetamine psychosis
methamphetamine psychosis
methamphetamine uses = associated psychosis
methamphetamine associated psychosis
methamphetamine dependence patients psychosis
methamphetamine use co personality antisocial
methamphetamine use co personality
methamphetamine dependence cases screened symptoms psychotic
methamphetamine dependence cases screened symptoms
Aconitine induced Ca causes apoptosis arrhythmia
aconitine cardiotoxicity
aconitine poisoning
aconitine poisoning
aconitine aggravates causes arrhythmia
cromakalim induced hypotension
pinacidil cromakalim induced hypotension
cromakalim induced hypotension vessels Vasodilation affected abolished tachycardia
pinacidil cromakalim induced hypotension vessels Vasodilation affected abolished tachycardia
Caffeine challenge test disorder panic
Caffeine challenge test disorder
Caffeine challenge test attacks panic
Caffeine challenge test attacks
caffeine test respond patients disorder panic
caffeine test respond patients disorder
caffeine test respond patients disorder PD
caffeine test respond patients disorder patients depression attacks panic
caffeine test respond patients disorder patients depression attacks
caffeine test respond induction attacks panic
caffeine test respond induction attacks
caffeine sensitive patients PD
caffeine observed attack panic
caffeine observed attack
caffeine test associated associated is association attacks panic
caffeine test associated associated is association attacks
caffeine test associated associated PD
trimethoprim induced crisis hemolytic
trimethoprim induced crisis anemia
sulfomethoxazole year girl had crisis hemolytic
sulfomethoxazole year girl had crisis anemia
isoproterenol extract investigate was induced cardiotoxicity
dobutamine occurs left
dobutamine occurs dysfunction ventricular
dobutamine occurs dysfunction
dobutamine results left
dobutamine results left dysfunction ventricular
dobutamine results left dysfunction
dobutamine results left dysfunction presumed stunning myocardial
dobutamine results left dysfunction presumed stunning
paracetamol due failure acute
paracetamol due failure liver
paracetamol due failure
paracetamol overdose greater patients failure acute
paracetamol overdose greater patients failure liver
paracetamol overdose greater patients failure
ibuprofen hypertension Pulmonary
ibuprofen hypertension
ibuprofen administration arteriosus report cases hypoxaemia
ibuprofen arteriosus report cases hypoxaemia
ibuprofen administration occurs hypoxaemia
Neuroleptic associated hyperprolactinemia
neuroleptic medications associated oligomenorrhea
medications associated oligomenorrhea
neuroleptic medications associated oligomenorrhea treated outpatients hyperprolactinemia
medications associated oligomenorrhea treated outpatients hyperprolactinemia
neuroleptic medications associated oligomenorrhea treated outpatients hyperprolactinemia amenorrhea
medications associated oligomenorrhea treated outpatients hyperprolactinemia amenorrhea
bromocriptine taking developed symptoms psychiatric
bromocriptine taking developed symptoms
neuroleptic galactorrhea hyperprolactinemia
neuroleptic galactorrhea hyperprolactinemia amenorrhea
rifampicin due Acute
rifampicin due failure renal
rifampicin due failure
Metolachlor UNASSIGNED classified based neoplasms liver
Metolachlor UNASSIGNED classified based neoplasms
metolachlor liver
metolachlor cancer
metolachlor cancer association suggestion finding neoplasms liver
metolachlor cancer association suggestion finding neoplasms
metolachlor use effects up follow warrant findings cancer liver
metolachlor use effects up follow warrant findings cancer
epinephrine appeared VT
epinephrine dogs susceptible VT
Vigabatrin history associated defects visual
Vigabatrin history associated defects field
Vigabatrin history associated defects
Vigabatrin have known patients group determine history defects visual
Vigabatrin have known patients group determine history defects field
Vigabatrin have known patients group determine history defects
Vigabatrin therapy due presumed defects visual
Vigabatrin therapy due presumed defects field
Vigabatrin therapy due presumed defects
Vigabatrin associated defects visual
Vigabatrin associated defects field
Vigabatrin associated defects
dipyridamole ischemia myocardial
dipyridamole ischemia
picrotoxin microperfusion induced effect acetate seizures
picrotoxin doses treated animals s number seizures
picrotoxin doses treated animals s + was duration seizure
picrotoxin microperfusion h prevented seizures
Rifampicin glomerulonephritis
rifampicin therapy complication reported glomerulonephritis
rifampicin treated failure acute
rifampicin treated failure renal
rifampicin treated failure
rifampicin therapy complication literature review treated failure acute
rifampicin therapy complication literature review treated failure renal
rifampicin therapy complication literature review treated failure
rifampicin treated secondary glomerulonephritis
rifampicin therapy complication literature review treated secondary glomerulonephritis
cyclophosphamide induced cystitis
CYP cyclophosphamide induced cystitis
puromycin administration developed model sclerosis focal
puromycin administration developed model sclerosis segmental
puromycin administration developed model sclerosis glomerular
puromycin administration developed model sclerosis
aminonucleoside administration developed model sclerosis focal
aminonucleoside administration developed model sclerosis segmental
aminonucleoside administration developed model sclerosis glomerular
aminonucleoside administration developed model sclerosis
puromycin administration developed model sclerosis FSGS
aminonucleoside administration developed model sclerosis FSGS
AMNS aminonucleoside administration developed model sclerosis focal
AMNS aminonucleoside administration developed model sclerosis segmental
AMNS aminonucleoside administration developed model sclerosis glomerular
AMNS aminonucleoside administration developed model sclerosis
AMNS aminonucleoside administration developed model sclerosis FSGS
AMNS toxicity enhances produces FSGS
AMNS toxicity enhances produces rats resulting end
AMNS toxicity enhances produces rats disease stage
AMNS toxicity enhances produces rats disease renal
AMNS toxicity enhances produces rats disease
Ethambutol known cause neuropathy polyneuropathy
Ethambutol known cause neuropathy optic
Ethambutol known cause neuropathy
ethambutol dose developed loss paresthesias
ethambutol dose developed loss visual
ethambutol dose developed loss
Thalidomide sensory
Thalidomide neurotoxicity
thalidomide doses treated patients confirmed incidence neuropathy sensory
thalidomide doses treated patients confirmed incidence neuropathy axonal
thalidomide doses treated patients confirmed incidence neuropathy
vincristine Effect sulfate infections Pseudomonas
vincristine Effect sulfate infections
sulfate infections Pseudomonas
sulfate infections
vincristine sulfate mg inoculation Intravenous followed leukopenia
sulfate mg inoculation Intravenous followed leukopenia
methylprednisolone acetate injection reported Two occlusions cases artery retinal
methylprednisolone acetate injection reported Two occlusions cases artery
methylprednisolone acetate injection reported Two occlusions cases artery and
methylprednisolone acetate injection reported Two occlusions cases artery choriocapillaris
methylprednisolone acetate injection reported Two occlusions
acetate injection reported Two occlusions cases artery retinal
acetate injection reported Two occlusions cases artery
acetate injection reported Two occlusions cases artery and
acetate injection reported Two occlusions cases artery choriocapillaris
acetate injection reported Two occlusions
PTU therapy stopping weeks resolved symptoms fever polyarthralgia
PTU discontinuing increased developed fever polyarthralgia
PTU therapy stopping weeks resolved symptoms fever ulcers oral
PTU therapy stopping weeks resolved symptoms fever ulcers
PTU discontinuing increased developed fever ulcers oral
PTU discontinuing increased developed fever ulcers
PTU therapy stopping weeks resolved symptoms fever
PTU discontinuing increased developed fever
amphetamine dehydroepiandrosterone Effects models schizophrenia
haloperidol induced used tests catalepsy
apomorphine haloperidol induced used models schizophrenia
Amphetamine induced apomorphine haloperidol induced used models schizophrenia
haloperidol induced used models schizophrenia
haloperidol groups difference test catalepsy
Lithium implicated changed induced DI nephrogenic
Lithium implicated changed induced DI
Lithium implicated changed focus DI nephrogenic
Lithium implicated changed focus DI
lithium received DI nephrogenic
lithium received DI
lithium received DI induced changed focus DI nephrogenic
lithium received DI induced changed focus DI
lithium treating induced DI nephrogenic
lithium treating induced DI
lithium treating induced developed secondary DI neurogenic
lithium treating induced developed secondary DI
isoniazid induced convulsions
strophantine G used types arrhythmia
G used types arrhythmia
BaCl used types arrhythmia
2 BaCl used types arrhythmia
chloroform BaCl used types arrhythmia
adrenaline used types arrhythmia
aconitine used used types arrhythmia
BaCl induced induced arrhythmia inhibition causing manifests models arrhythmia
2 BaCl induced induced arrhythmia inhibition causing manifests models arrhythmia
BaCl induced induced arrhythmia
2 BaCl induced induced arrhythmia
chloroform induced arrhythmia inhibition causing manifests models arrhythmia
chloroform induced arrhythmia
adrenaline chloroform induced arrhythmia inhibition causing manifests models arrhythmia
adrenaline chloroform induced arrhythmia
Suxamethonium induced stiffness jaw
Suxamethonium induced stiffness
Suxamethonium induced stiffness myalgia
suxamethonium occur rigidity prolonged
suxamethonium occur rigidity jaw
suxamethonium occur rigidity
suxamethonium occur rigidity myalgia
diethylpropion efficacy evaluating study subject man became manic
DEP man became manic
DEP different observed subjects become manic
1 induced syndrome Milk
1 induced syndrome alkali
1 induced syndrome
25 1 induced syndrome Milk
25 1 induced syndrome alkali
25 1 induced syndrome
OH 1 induced syndrome Milk
OH 1 induced syndrome alkali
OH 1 induced syndrome
2 D 1 induced syndrome Milk
2 D 1 induced syndrome alkali
2 D 1 induced syndrome
D 1 induced syndrome Milk
D 1 induced syndrome alkali
D 1 induced syndrome
calcium amounts described Milk
calcium amounts described syndrome alkali
calcium amounts described syndrome
alkali calcium amounts described Milk
alkali calcium amounts described syndrome alkali
alkali calcium amounts described syndrome
calcitriol carbonate treated resulting hospital milk
calcitriol carbonate treated hypoparathyroidism syndrome alkali
calcitriol carbonate treated hypoparathyroidism syndrome
calcium carbonate treated resulting hospital milk
calcium carbonate treated hypoparathyroidism syndrome alkali
calcium carbonate treated hypoparathyroidism syndrome
carbonate treated resulting hospital milk
carbonate treated hypoparathyroidism syndrome alkali
carbonate treated hypoparathyroidism syndrome
epirubicine cardiotoxicity
streptozotocin rats diabetic
isoproterenol study induced fibrosis
streptozotocin diabetes
ISO given appeared analyzed fibrosis
ISO fibrosis
streptozotocin causes points effect sensitivity rats diabetic
puromycin nephropathy
aminonucleoside nephropathy
puromycin aminonucleoside nephropathy
aminonucleoside nephropathy
puromycin aminonucleoside exacerbates model disease glomerular
puromycin aminonucleoside exacerbates model disease
aminonucleoside exacerbates model disease glomerular
aminonucleoside exacerbates model disease
PAN aminonucleoside nephropathy
PAN aminonucleoside exacerbates model disease glomerular
PAN aminonucleoside exacerbates model disease
PAN nephropathy
PAN injections induced glomerulopathy
PAN nephropathy
PAN animals nephropathy
PAN nephropathy
PAN nephropathy
fluorescein injection followed Tonic
fluorescein injection followed seizures clonic
fluorescein injection followed seizures
quinine infusion getting reported presented arrhythmia contraction premature
quinine infusion getting reported presented arrhythmia contraction ventricular
quinine infusion getting reported presented arrhythmia contraction
quinine infusion hours felt showed > contraction premature
quinine infusion hours felt showed > contraction ventricular
quinine infusion hours felt showed > contraction
quinine infusion hours felt showed > contraction PVC
Quinine alkaloid arrhythmia PVC
suxamethonium pains
scoline pain
scoline pain
scoline pain
scoline pain occurrence influence abolition fasciculations
suxamethonium preparation type used affected incidence pain
scoline pain
iAs exposure development relationship cancer
iAs exposure life OBJECTIVES research underlie risk development cancer
iAs elicits DISCUSSION Epigenetic reprogramming plausible changes expression development cells cancer
iAs exposure development cancer
phenylpropanolamine antagonism hypertension
Phenylpropanolamine cause hypertension
PPA Phenylpropanolamine cause hypertension
PPA treatment hypertension
hepatitis carriers DNA hepatitis
hepatitis carriers DNA B
B carriers DNA hepatitis
B carriers DNA B
surface carriers DNA hepatitis
surface carriers DNA B
antigen carriers DNA hepatitis
antigen carriers DNA B
methimazole case hepatitis cases necrosis hepatocellular
methimazole case hepatitis cases necrosis
propylthiouracil cases hepatitis
propylthiouracil case necrosis cases hepatitis
propylthiouracil cases associated lupus
propylthiouracil cases described syndrome like
propylthiouracil cases described syndrome
propylthiouracil case necrosis cases associated lupus
propylthiouracil case necrosis cases described syndrome like
propylthiouracil case necrosis cases described syndrome
Fluconazole agranulocytosis
Fluconazole agranulocytosis thrombocytopenia
fluconazole agranulocytosis
fluconazole agranulocytosis thrombocytopenia
fluconazole therapy result probable occurred algorithm agranulocytosis
fluconazole therapy result probable occurred thrombocytopenia
Indomethacin induced hyperkalemia
indomethacin developed severe life hyperkalemia
indomethacin developed severe life hyperkalemia insufficiency renal
indomethacin developed severe life hyperkalemia insufficiency
Cephalothin induced anemia hemolytic
Cephalothin induced anemia
cephalothin therapy receiving anemia hemolytic
cephalothin therapy receiving anemia
levodopa dyskinesias
levodopa dyskinesias LIDs
acetaminophen celecoxib patients reactions skin
acetaminophen celecoxib patients reactions
paracetamol acetaminophen celecoxib patients reactions skin
paracetamol acetaminophen celecoxib patients reactions
nimesulide celecoxib patients reactions skin
nimesulide celecoxib patients reactions
P reactions cutaneous
P reactions
N P reactions cutaneous
N P reactions
P diagnosis based reactions skin
P diagnosis based reactions
N P diagnosis based reactions skin
N P diagnosis based reactions
ibuprofen administration followed pain
ibuprofen administration followed pain increase correlates pain
ibuprofen administration followed indicating interaction stimuli pain
ibuprofen effect indicating followed pain
ibuprofen effect indicating followed pain increase correlates pain
ibuprofen effect indicating interaction stimuli pain
risperidone 0 8 induced N hyperprolactinemia
risperidone pseudoprolactinoma associated 0 hyperprolactinemia
adriamycin induced injury mitochondrial
adriamycin induced injury
ADR HNE showed point appeared injury mitochondrial
ADR HNE showed point appeared injury
Vincristine use reported hormone Hyponatremia
Vincristine use reported hormone Hyponatremia syndrome
Vincristine use reported hormone Hyponatremia anti of
Vincristine use reported hormone Hyponatremia anti inappropriate
Vincristine use reported hormone Hyponatremia anti
Vincristine use reported hormone diuretic
Vincristine use reported hormone
vincristine hormone secretion syndrome rate hyponatremia
vincristine hormone secretion syndrome
vincristine hormone secretion of
vincristine hormone secretion inappropriate
vincristine hormone secretion
vincristine hormone secretion anti of
vincristine hormone secretion anti
vincristine hormone diuretic
vincristine hormone
vincristine hormone SIADH
vincristine use reported reported cases hyponatremia
vincristine use reported reported cases SIADH
vincristine use associated SIADH cases hyponatremia
vincristine use associated SIADH
vincristine use associated suggest risk hyponatremia
vincristine use associated suggest SIADH
vincristine associated SIADH
desvenlafaxine associated Syndrome
desvenlafaxine associated Syndrome secretion of
desvenlafaxine associated Syndrome secretion inappropriate
desvenlafaxine associated Syndrome secretion antidiuretic
desvenlafaxine associated Syndrome secretion hormone
desvenlafaxine associated secretion case syndrome
desvenlafaxine associated secretion case syndrome anti of
desvenlafaxine associated secretion case syndrome anti inappropriate
desvenlafaxine associated secretion case syndrome anti
desvenlafaxine associated secretion diuretic
desvenlafaxine associated secretion hormone
desvenlafaxine associated secretion SIADH
desvenlafaxine included included nausea confusion
desvenlafaxine included included nausea anxiety
desvenlafaxine included included nausea
desvenlafaxine cause hyponatremia
kanamycin protects zinc induced hearing
kanamycin protects zinc induced hearing loss
paclitaxel combination dosed appear add toxicities hematologic
paclitaxel combination dosed appear add toxicities
doxorubicin demonstrated agent limiting erythrodysesthesia
doxorubicin demonstrated hand
doxorubicin demonstrated hand foot -
doxorubicin demonstrated hand foot
doxorubicin demonstrated hand syndrome
Doxil doxorubicin demonstrated agent limiting erythrodysesthesia
Doxil doxorubicin demonstrated hand
Doxil doxorubicin demonstrated hand foot -
Doxil doxorubicin demonstrated hand foot
Doxil doxorubicin demonstrated hand syndrome
doxorubicin demonstrated stomatitis
Doxil doxorubicin demonstrated stomatitis
doxorubicin results toxicity stomatitis hand
doxorubicin results toxicity stomatitis syndrome foot
doxorubicin results toxicity stomatitis syndrome
doxorubicin results toxicity stomatitis
tropicamide dilation effect pupil
tropicamide dilation
tropicamide dilation pupil
tropicamide dilation
Zidovudine induced hepatitis
zidovudine patient induced hepatitis
caffeine exposure induce retardation intrauterine
caffeine exposure induce retardation growth
caffeine exposure induce retardation
caffeine exposure induce retardation IUGR
Sotalol induced spasm coronary
Sotalol induced spasm
sotalol properties blocking induced vasospasm Coronary
sotalol properties blocking induced vasospasm
GTN administration pressure drop
GTN administration pressure drop blood in
GTN administration pressure drop blood
GTN administration pressure
GTN minutes experienced drop
GTN minutes experienced pressure in
GTN minutes experienced pressure blood
GTN minutes experienced pressure
isradipine reported frequent headache
isradipine reported frequent headache flushing
isradipine reported frequent headache dizziness
bupivacaine doses increase shown Pre induced cardiotoxicity
bupivacaine alleviate shown Pre induced cardiotoxicity
bupivacaine induced cardiotoxicity
bupivacaine consumption amount asystole
bupivacaine onset delayed treatment pre induced effects cardiotoxic
bupivacaine levels effects cardiotoxic
suxamethonium apnea
suxamethonium characterized apnea
mivacurium suxamethonium characterized deficiency Butyrylcholinesterase
mivacurium suxamethonium characterized deficiency
mivacurium suxamethonium characterized apnea
suxamethonium characterized deficiency Butyrylcholinesterase
suxamethonium characterized deficiency
phenylephrine effect ischemia hypertension
phenylephrine effect determined min occlusion rats hypertensive
phenylephrine effect induced hypertension
phenobarbital administration linked proliferation hepatomegaly
thalidomide completed men found evidence neuropathy peripheral
thalidomide completed men found evidence neuropathy
thalidomide option patients failed maintained development neuropathy peripheral
thalidomide option patients failed maintained development neuropathy
bortezomib fasciitis Necrotising
bortezomib fasciitis
dexamethasone bortezomib fasciitis Necrotising
dexamethasone bortezomib fasciitis
bortezomib dose treatment suffered fasciitis necrotising
bortezomib dose treatment suffered fasciitis
dexamethasone dose treatment suffered fasciitis necrotising
dexamethasone dose treatment suffered fasciitis
argatroban bleeding
5 cisplatin receiving patients Hypotension
fluorouracil Hypotension
cisplatin receiving patients Hypotension
5 cisplatin treated developed symptoms hypotension
fluorouracil 5 cisplatin treated developed symptoms hypotension
5 fluorouracil 5 cisplatin treated developed symptoms hypotension
FU 5 fluorouracil 5 cisplatin treated developed symptoms hypotension
cisplatin treated developed symptoms hypotension
CDDP cisplatin treated developed symptoms hypotension
vincristine Syndrome
vincristine Syndrome secretion of
vincristine Syndrome secretion inappropriate
vincristine Syndrome secretion
vincristine Syndrome hormone of
vincristine Syndrome hormone antidiuretic
vincristine Syndrome hormone
vincristine infusion attributed hormone secretion syndrome
vincristine infusion attributed hormone secretion of
vincristine infusion attributed hormone secretion inappropriate
vincristine infusion attributed hormone secretion
vincristine infusion attributed hormone of
vincristine infusion attributed hormone antidiuretic
vincristine infusion attributed hormone
methylphenidate syndrome Neuroleptic
methylphenidate syndrome malignant
methylphenidate syndrome
methylphenidate caused syndrome neuroleptic
methylphenidate caused syndrome malignant
methylphenidate caused syndrome
methylphenidate caused syndrome neuroleptic
methylphenidate caused syndrome malignant
methylphenidate caused syndrome
Minocycline induced fulfilling criteria nodosa polyarteritis
Minocycline induced fulfilling criteria nodosa
fluoxetine treatment associated Mania
fluoxetine reported induce mania
fluoxetine developed mania
fluoxetine pharmacotherapy mania
fluoxetine pharmacotherapy mania hypomania
fluoxetine pharmacotherapy mania development factors combination disorder bipolar
fluoxetine pharmacotherapy mania development factors combination disorder
fluoxetine pharmacotherapy mania development factors combination diagnosis disorder bipolar
fluoxetine pharmacotherapy mania development factors combination diagnosis disorder
fluoxetine mania
sumatriptan Transmural infarction myocardial
sumatriptan Transmural infarction
sumatriptan subcutaneously administration describe 47 woman infarction myocardial
sumatriptan subcutaneously administration describe 47 woman infarction
warfarin induced epiphyses hypoplasia stippled
warfarin induced epiphyses
warfarin induced epiphyses punctata chondrodysplasia
warfarin induced epiphyses punctata
warfarin treated mothers born infants reported hypoplasia epiphyses stippled
warfarin treated mothers born infants reported hypoplasia epiphyses
d antagonists induced hypotension
tubocurarine antagonists induced hypotension
carmustine explore aimed study dysfunction cognitive
carmustine explore aimed study dysfunction
BCNU carmustine explore aimed study dysfunction cognitive
BCNU carmustine explore aimed study dysfunction
biperiden due Bradycardia
biperiden induced Bradycardia
verapamil resulting block atrioventricular
verapamil resulting block AV
verapamil resulting block
clonidine interaction cases report resulting block hypotension
clonidine interaction cases report resulting block atrioventricular
clonidine interaction cases report resulting block AV
clonidine interaction cases report resulting block
verapamil resulting block hypotension
clonidine dose addition developed block hypotension
clonidine dose addition developed block AV
clonidine dose addition developed block
clonidine bid addition developed block AV
clonidine bid addition developed block
melphalan dose Acute
melphalan dose Acute insufficiency renal
melphalan dose Acute insufficiency
melphalan conditioning noted development insufficiency acute
melphalan conditioning noted development insufficiency renal
melphalan conditioning noted development insufficiency
melphalan defined high insufficiency Acute
melphalan defined high insufficiency renal
melphalan defined high insufficiency
melphalan defined high insufficiency ARI
melphalan dose RESULTS developed ARI
melphalan underwent Patients had ARI
melphalan suggests timing injury renal
melphalan suggests timing injury
melphalan injury renal
melphalan injury
Acetaminophen produces necrosis tubular
Acetaminophen produces necrosis
APAP Acetaminophen produces necrosis tubular
APAP Acetaminophen produces necrosis
APAP induced necrosis renal
APAP induced necrosis tubular
APAP induced necrosis
PAP formation accounts APAP induced necrosis renal
PAP formation accounts APAP induced necrosis tubular
PAP formation accounts APAP induced necrosis
Epsilon acid used prevent rebleeding patients hemorrhage subarachnoid
Epsilon acid used prevent rebleeding patients hemorrhage
aminocaproic acid used prevent rebleeding patients hemorrhage subarachnoid
aminocaproic acid used prevent rebleeding patients hemorrhage
acid used prevent rebleeding patients hemorrhage subarachnoid
acid used prevent rebleeding patients hemorrhage
Epsilon acid used prevent rebleeding patients hemorrhage SAH
aminocaproic acid used prevent rebleeding patients hemorrhage SAH
acid used prevent rebleeding patients hemorrhage SAH
EACA acid used prevent rebleeding patients hemorrhage subarachnoid
EACA acid used prevent rebleeding patients hemorrhage
EACA acid used prevent rebleeding patients hemorrhage SAH
EACA therapy complications thrombotic
EACA treated syndromes included thrombi
EACA treated syndromes included deterioration thrombosis intracranial
EACA treated syndromes included deterioration thrombosis vascular
EACA treated syndromes included deterioration thrombosis
EACA treated syndromes included thrombi arteriolar SAH
EACA implicated observed thrombi
EACA implicated pathogenesis thrombi
EACA therapy occurred patient SAH
EACA therapy occurred patient documentation SAH
acetaminophen edema cerebral
acetaminophen edema
acetaminophen edema based unit facility 27 female FHF
acetaminophen edema cerebral
acetaminophen edema
acetaminophen confirmed FHF
acetaminophen overdose edema cerebral
acetaminophen overdose edema
acetaminophen overdose edema patients FHF
ketoconazole using presented eruption maculopapular
ketoconazole using presented eruption
heparin Incidence II thrombocytopenia
heparin Incidence II type
heparin Incidence II
heparin impact induced II thrombocytopenia
heparin impact induced II type
heparin impact induced II
heparin impact induced II II HIT
heparin impact induced II II type
heparin impact induced II II
heparin impact induced cause thrombocytopenia
heparin use avoided reduction II HIT
heparin use avoided reduction II type
heparin use avoided reduction II
heparin weight performed avoided reduction II HIT
heparin weight performed avoided reduction II type
heparin weight performed avoided reduction II
morphine administration nystagmus Downbeat
morphine administration nystagmus
morphine controlled IMPLICATIONS case documents patient developed downbeating
morphine controlled IMPLICATIONS case documents patient developed downbeating nystagmus
morphine controlled IMPLICATIONS case documents patient developed dizziness
cyclosporine recipients infections
cyclosporine patients had infections
cyclosporine patients had infections infections
Aza patients had infections
Aza patients had infections infections
cyclosporine patients infections
cyclosporine patients infections infections
Aza patients had infections infections
Aza patients had infections
cyclosporine patients deaths were played infection
Aza cyclosporine patients deaths were played infection
cyclosporine common infections
Aza treated cyclosporine common infections
Flurothyl ether produced hypothermia
Flurothyl ether produced unclear relationship hypothermia
flurothyl exposure duration correlated hypothermia
flurothyl exposure duration correlated hypothermia produced unclear relationship hypothermia
aspirin analgesic use Studies drugs end
aspirin analgesic use Studies BACKGROUND stage
aspirin analgesic use Studies BACKGROUND stage given disease renal
aspirin analgesic use Studies BACKGROUND stage given disease
aspirin analgesic use Studies BACKGROUND stage given disease ESRD
aspirin associated ESRD
aspirin use increase risk ESRD
sirolimus role anemia
Sirolimus implicated playing anemia
rapamycin inhibitor target Sirolimus implicated playing anemia
sirolimus associated anemia
clonidine brain pathway Participation hypotension
clonidine brain pathway Participation hypotension bradycardia
clonidine induced antagonized hypotension
clonidine bradycardia
clonidine reduced magnitude vasodepressor responses bradycardiac
clonidine development involved hypotension
clonidine development involved hypotension bradycardia
heparin aspects thrombocytopenia
heparin therapy thrombocytopenia
heparin therapy effects include heparin induced heparin osteoporosis alopecia hypoaldosteronism
heparin induced heparin osteoporosis alopecia hypoaldosteronism
heparin osteoporosis alopecia hypoaldosteronism
heparin therapy effects include heparin induced heparin osteoporosis
heparin induced heparin osteoporosis
heparin osteoporosis
heparin therapy effects include heparin induced heparin osteoporosis eosinophilia
heparin induced heparin osteoporosis eosinophilia
heparin osteoporosis eosinophilia
heparin therapy effects include heparin induced heparin osteoporosis reactions skin
heparin therapy effects include heparin induced heparin osteoporosis reactions
heparin induced heparin osteoporosis reactions skin
heparin induced heparin osteoporosis reactions
heparin osteoporosis reactions skin
heparin osteoporosis reactions
heparin therapy effects include heparin induced heparin osteoporosis alopecia hyperkalemia
heparin induced heparin osteoporosis alopecia hyperkalemia
heparin osteoporosis alopecia hyperkalemia
heparin therapy effects include heparin induced heparin osteoporosis alopecia
heparin induced heparin osteoporosis alopecia
heparin osteoporosis alopecia
heparin therapy effects include heparin induced thrombocytopenia
heparin therapy effects include heparin induced heparin osteoporosis reactions thrombocytopenia
heparin induced thrombocytopenia
heparin induced heparin osteoporosis reactions thrombocytopenia
heparin induced thrombocytopenia
heparin osteoporosis reactions thrombocytopenia
heparin therapy effects include heparin induced heparin osteoporosis alopecia priapism
heparin induced heparin osteoporosis alopecia priapism
heparin osteoporosis alopecia priapism
heparin therapy effects include heparin induced heparin osteoporosis reactions allergic
heparin therapy effects include heparin induced heparin osteoporosis reactions
heparin induced heparin osteoporosis reactions allergic
heparin induced heparin osteoporosis reactions
heparin osteoporosis reactions allergic
heparin osteoporosis reactions
heparin use common osteoporosis
dobutamine response Hypertensive
dobutamine studies occurred response hypertensive
dobutamine infusion had had history hypertension
cocaine amount causes deterioration
cocaine amount causes deterioration ventricular of
cocaine amount causes deterioration ventricular left
cocaine amount causes deterioration ventricular
cocaine amount causes deterioration ventricular LV
cocaine amount causes deterioration ventricular function systolic
cocaine amount causes deterioration ventricular function
cocaine infusion causes performance deterioration
cocaine infusion causes performance deterioration LV of
cocaine infusion causes performance deterioration LV
cocaine infusion causes performance systolic
cocaine infusion causes performance systolic and
cocaine infusion causes performance systolic diastolic
cocaine infusion causes performance
digoxin has effects increasing causing arrhythmias
indomethacin induced Hyperkalemia
naproxen indomethacin induced Hyperkalemia
indomethacin caused hypoaldosteronism
mefenamic nephropathy
acid nephropathy
indomethacin caused hypoaldosteronism hyperkalemia
naproxen indomethacin caused hypoaldosteronism
naproxen indomethacin caused hypoaldosteronism hyperkalemia
indomethacin therapy allowing correcting hyperkalemia
etomidate prove hypnotic choice technique adults incidence myoclonia
amisulpride overdose cases cause syndrome prolonged
amisulpride overdose cases cause syndrome QT
amisulpride overdose cases cause syndrome
Caffeine produced subject anxiety tremors
Caffeine produced subject anxiety
Caffeine produced subject anxiety nausea
caffeine avoiding benefit Patients disorders anxiety
caffeine avoiding benefit Patients disorders
levodopa factors dyskinesia
levodopa therapy leads development fluctuations dyskinesia
levodopa predictors dyskinesia
levodopa therapy present Dyskinesia
levodopa therapy duration age had Patients dyskinesia
levodopa therapy duration age had dyskinesia
levodopa dose total age had Patients dyskinesia
levodopa dose total age had dyskinesia
levodopa therapy duration predictors dyskinesia
levodopa dose therapy duration predictors dyskinesia
levodopa prevalence CONCLUSIONS % dyskinesia
tranexamic acid seizures convulsive
acid seizures convulsive
tranexamic acid seizures
acid seizures
tranexamic acid aorta ascending calcification surgery redo included predictors seizures
acid aorta ascending calcification surgery redo included predictors seizures
tranexamic acid predictor seizures
acid predictor seizures
tranexamic acid factor weighed risk seizures
acid factor weighed risk seizures
cimetidine caused hypotension
cimetidine activity mediated useful preventing hypotension
DOX induced failure heart
DOX induced failure
Methyldopa induced anemia hemolytic
Methyldopa induced anemia
methyldopa case report syncope anemia hemolytic
methyldopa case report syncope anemia
DOCA pathogenesis plays hypertension
DOCA treated hypertension
lithium rats substantial hypertension treated insipidus diabetes
lithium rats substantial hypertension treated insipidus
warfarin anticoagulant causing hemorrhage intracerebral
warfarin anticoagulant causing hemorrhage
haloperidol releasing induced hyperprolactinemia
haloperidol infusions course found hyperprolactinemia
levobupivacaine injection seizures grand
levobupivacaine injection seizures mal
levobupivacaine injection seizures
levobupivacaine % microgram mL administration developed seizures grand
levobupivacaine % microgram mL administration developed seizures mal
levobupivacaine % microgram mL administration developed seizures
morphine induced hyperactivity
morphine prevented blockers K induced morphine induced hyperactivity
morphine prevent sufficient suggested induced morphine seems hyperactivity
morphine seems hyperactivity
temsirolimus patchy limited found areas compatible post repair necrotic
Adrenaline induced used hypertension
adrenaline giving using evaluated BBB destroy used hypertension
levobupivacaine received occurred collapse cardiovascular
levobupivacaine received occurred collapse
apomorphine amnesia
scopolamine attenuates derivative induced learning
scopolamine attenuates derivative induced and
scopolamine attenuates derivative induced post
scopolamine attenuates derivative induced training
scopolamine attenuates derivative induced training deficits consolidation
scopolamine attenuates derivative induced training deficits
apomorphine inhibits evaluated amnesia
apomorphine induced amnesia
suxamethonium injection spasm muscle
suxamethonium injection spasm
Dimer had incidence nausea dizziness
X group had incidence nausea dizziness
Dimer had incidence nausea
X group had incidence nausea
Endografine group had incidence pain abdominal
Endografine group had incidence pain
Quetiapine induced neutropenia
Quetiapine derivative has risk causing dyscrasias neutropenia
quetiapine developed neutropenia
quetiapine treated developed leucopenia
quetiapine effect neutropenia
quetiapine marker fever
capsaicin injections glutamate variability hyperalgesia
capsaicin injections glutamate variability hyperalgesia allodynia
capsaicin glutamate injections attractive use mimic hyperalgesia
capsaicin glutamate injections attractive use mimic hyperalgesia allodynia
capsaicin detected hyperalgesia
Capsaicin injection reproducible hyperalgesia secondary
Capsaicin injection reproducible hyperalgesia
Capsaicin injection reproducible hyperalgesia allodynia
capsaicin conclusion yield hyperalgesic
capsaicin conclusion yield hyperalgesic responses allodynic
corticosteroid treated carcinoma Hepatocellular
corticosteroid treated carcinoma
androgen treated carcinoma Hepatocellular
androgen treated carcinoma
corticosteroid non metastasizing develop neoplasms peliosis
androgen patients develop neoplasms peliosis
vigabatrin specific defects Binasal
vigabatrin specific defects visual
vigabatrin specific defects field
vigabatrin specific defects
vigabatrin associated defects visual
vigabatrin associated defects
VGB vigabatrin associated defects visual
VGB vigabatrin associated defects
VGB associated toxicity retinal
VGB associated toxicity
pilocarpine seizures
pilocarpine installation frequency epilepticus status
pilocarpine installation frequency epilepticus
pilocarpine installation frequency epilepticus demonstrated seizure
non inhibitors risk infarction myocardial acute
non inhibitors risk infarction myocardial
non inhibitors risk infarction
steroidal anti OBJECTIVES risk infarction myocardial acute
steroidal anti OBJECTIVES risk infarction myocardial
steroidal anti OBJECTIVES risk infarction
anti OBJECTIVES risk infarction myocardial acute
anti OBJECTIVES risk infarction myocardial
anti OBJECTIVES risk infarction
inflammatory drugs anti OBJECTIVES risk infarction myocardial acute
inflammatory drugs anti OBJECTIVES risk infarction myocardial
inflammatory drugs anti OBJECTIVES risk infarction
drugs anti OBJECTIVES risk infarction myocardial acute
drugs anti OBJECTIVES risk infarction myocardial
drugs anti OBJECTIVES risk infarction
non inhibitors risk infarction AMI
steroidal anti OBJECTIVES risk infarction AMI
anti OBJECTIVES risk infarction AMI
inflammatory drugs anti OBJECTIVES risk infarction AMI
drugs anti OBJECTIVES risk infarction AMI
COX risk infarction myocardial acute
COX risk infarction myocardial
COX risk infarction
2 inhibitors risk infarction myocardial acute
2 inhibitors risk infarction myocardial
2 inhibitors risk infarction
inhibitors risk infarction myocardial acute
inhibitors risk infarction myocardial
inhibitors risk infarction
COX risk infarction AMI
2 inhibitors risk infarction AMI
inhibitors risk infarction AMI
COX NSAIDs using bleeding risks hospitalization AMI
2 inhibitors NSAIDs using bleeding risks hospitalization AMI
inhibitors NSAIDs using bleeding risks hospitalization AMI
rofecoxib group acetaminophen GI non users aspirin ratios hospitalization AMI
naproxen 1 27 group acetaminophen GI non users aspirin ratios hospitalization AMI
naproxen seemed carry risk GI
naproxen seemed carry risk GI bleeding
naproxen seemed carry risk GI AMI
rofecoxib those better seemed similar AMI
methotrexate Paraplegia
methotrexate instillation paraplegia
5 doses receiving patients patients patients seen levels onset hyperammonemia
FU doses receiving patients patients patients seen levels onset hyperammonemia
levodopa rigidity induced underwent dyskinesias
levodopa dose reduction useful drug
levodopa dose reduction useful dyskinesias induced
levodopa dose reduction useful dyskinesias
cyclophosphamide treated had hematuria
cyclophosphamide abnormalities indistinguishable carcinoma
VNR events risk similar vindesine VDS drugs cardiotoxic
fluoxetine occlusion vein retinal
fluoxetine occlusion vein
fluoxetine occlusion
fluoxetine associated case occlusion retinal
fluoxetine associated case occlusion vein
fluoxetine associated case occlusion
fluoxetine associated described hypertension
nafcillin nephritis interstitial
nafcillin nephritis
quetiapine doses high add agitation
quetiapine introduction h presented agitation
quetiapine reintroduction withdrawal led agitation
quetiapine reintroduction withdrawal enabled attribute agitation
quetiapine attribute enabled withdrawal led agitation
quetiapine attribute agitation
glibenclamide 1 fold 4 treatment associated hazard developing CAD
glibenclamide treatment CONCLUSIONS associated risk CAD
ecstasy users Dysfunctional
ecstasy users Dysfunctional consolidation overnight
ecstasy users Dysfunctional consolidation memory
ecstasy users marked neurocognitive sleep
ecstasy users marked neurocognitive impairments related
ecstasy users marked neurocognitive impairments
Ecstasy users demonstrated consolidation impaired
Ecstasy users demonstrated consolidation overnight
Ecstasy users demonstrated consolidation memory
ecstasy suggest underlie impairments memory
ecstasy suggest underlie impairments
ecstasy users underlie impairments memory
ecstasy users underlie impairments
carboplatin chemotherapy treated patients motility abnormal
carboplatin chemotherapy treated patients motility ocular
carboplatin chemotherapy treated patients motility
carboplatin received retinoblastoma noted motility abnormal
carboplatin received retinoblastoma noted motility ocular
carboplatin received retinoblastoma noted motility
carboplatin associated fibrosis
heparin patient alteplase thrombolysis Use thrombocytopenia
heparin induced thrombocytopenia
heparin embolism pulmonary
heparin embolism
heparin embolism venous upper induced thrombocytopenia
heparin embolism venous thrombosis DVT
valproic acid dementia
acid dementia
valproic year induced documented dementia
acid year induced documented dementia
valproic acid effect system effect mediated hyperammonemia
acid effect system effect mediated hyperammonemia
valproic hyperammonemia
acid hyperammonemia
amphetamine seizures
cocaine incidence seizures
amphetamine reducing incidence seizures
cocaine induced seizures
CE levels associated decrease
CE levels associated decrease output in
CE levels associated decrease output cardiac
CE levels associated decrease output
caffeine doses scored characteristics activity induction clonic
caffeine doses scored characteristics activity induction seizure
pilocarpine induced epilepticus status
pilocarpine induced epilepticus
Pilo pilocarpine induced epilepticus status
Pilo pilocarpine induced epilepticus
carbamazepine had had myocarditis
diazinon activation hyperlipemia
diazinon induced hyperlipemia
ADR nephropathy clearance uraemia
ADR progression rate induced glomerulosclerosis focal
ADR progression rate induced glomerulosclerosis segmental
ADR progression rate induced glomerulosclerosis
AVP effects rats hypertensive
arginine vasopressin influence compare peptide rats normotensive hypertensive
vasopressin influence compare peptide rats normotensive hypertensive
AVP vasopressin influence compare peptide rats normotensive hypertensive
phenylephrine determined induced nitroprusside hypertension
Phe phenylephrine determined induced nitroprusside hypertension
sodium hypertension nitroprusside induced determined hypotension
nitroprusside induced determined hypotension
SN nitroprusside induced determined hypotension
SN reduced hypotension
hydroxychloroquine taking patients loss visual
hydroxychloroquine taking patients loss field
hydroxychloroquine taking patients loss
hydroxychloroquine attributed abnormalities visual
hydroxychloroquine attributed abnormalities field
hydroxychloroquine attributed abnormalities
haloperidol role induced catalepsy
pilocarpine cholinomimetic doses induce catalepsy
haloperidol blocker induced catalepsy
pilocarpine doses caused enhancement catalepsy
haloperidol induced catalepsy
haloperidol induced catalepsy
haloperidol neuroleptics produced catalepsy
lorazepam therapy associated Myoclonus
lorazepam administration myoclonus
lithium therapy developed bradyarrhythmia hypercalcemia
lithium therapy receiving patient findings prompted conduct lithium associated hypercalcemia
lithium conduct prompted findings patient receiving therapy developed bradyarrhythmia hypercalcemia
lithium associated hypercalcemia
lithium non identified eliminating hypercalcemias
lithium non treated hypercalcemias
lithium non hypercalcemia
lithium patients conditions malignancies related hypercalcemias treated non identified eliminating hypercalcemias
lithium patients conditions malignancies related hypercalcemias
lithium patients conditions malignancies related hypercalcemias treated non hypercalcemia
lithium resulting Patients hypercalcemia
lithium resulting had hypercalcemia
botox injection dysphonia adductor
botox injection dysphonia spasmodic
botox injection dysphonia
Botox injections standard care dysphonia adductor
Botox injections standard care dysphonia spasmodic
Botox injections standard care dysphonia
Botox injections standard care dysphonia ADSD
Botox injections ADSD
Botox receiving diagnosed ADSD
Botox injection ADSD
Botox injections ADSD
pilocarpine seizures
pilocarpine injections induced seizures
Fluvastatin Therapy Injury Drug
Fluvastatin Therapy Injury Induced
Fluvastatin Therapy Injury Acute
Fluvastatin Therapy Injury Liver
Fluvastatin Therapy Injury
fluvastatin beginning appeared damage liver
fluvastatin beginning appeared damage
picrotoxin aspartate N induced convulsions observed observed convulsions
picrotoxin aspartate N induced convulsions
bemegride pentylenetetrazole induced convulsions
bemegride pentylenetetrazole induced convulsions observed observed convulsions
pentylenetetrazole induced convulsions
pentylenetetrazole induced convulsions observed observed convulsions
aracytine dose edema shock
C edema shock
aracytine dose edema Pulmonary
aracytine dose edema
C edema Pulmonary
C edema
Ara C associated hypothesize thought involved development shock
C associated hypothesize thought involved development shock
azathioprine effects include anemia
Azathioprine triggers death effect contributing azathioprine anemia
azathioprine anemia
diethylstilbesterol evidence induced carcinomas renal
diethylstilbesterol evidence induced carcinomas
diethylstilbesterol induced carcinomas renal
diethylstilbesterol induced carcinomas
TDF criteria records found had syndrome Fanconi
TDF criteria records found had syndrome
TDF effects hospitalisation incidence high patients features syndrome Fanconi
TDF effects hospitalisation incidence high patients features syndrome
carbamazepine associated cases nystagmus oscillopsia
Succimer chelation improves exposed produces impairment cognitive
Succimer chelation improves exposed produces impairment
rifampicin reintroduction induced failure 3 thrombopenia hemolysis
rifampicin reintroduction induced failure 3 thrombopenia
isoproterenol induced infarction myocardial
isoproterenol induced infarction
isoproterenol prevented treatment pre induced infarction myocardial
isoproterenol prevented treatment pre induced infarction
isoproterenol induced effect chebula injury myocardial
isoproterenol induced effect chebula injury
isoproterenol induced damage myocardial
isoproterenol induced damage
L observed Hypokalemia
dopa L observed Hypokalemia
L influence studied patients hypokalemia
dopa L influence studied patients hypokalemia
diethylcarbamazine loiasis cases encephalitis
diethylcarbamazine treatment encephalitis
DEC diethylcarbamazine treatment encephalitis
bromocriptine infarction myocardial
bromocriptine infarction
Bromocriptine implicated reports infarction myocardial
Bromocriptine implicated reports infarction
vincristine administration due myeloencephalopathy
Vincristine given producing encephalopathy
Vincristine given producing dysfunction sensory
Vincristine given producing dysfunction sensory and
Vincristine given producing dysfunction sensory motor
Vincristine given producing dysfunction
mirtazapine associated syndrome restless
mirtazapine associated syndrome legs
mirtazapine associated syndrome
Mirtazapine associated RLS
mirtazapine RLS
mirtazapine treated have symptoms RLS
mirtazapine treated have started resolved symptoms RLS
mirtazapine discontinuation resolved started have symptoms RLS
mirtazapine discontinuation resolved symptoms RLS
mirtazapine use symptoms RLS
mirtazapine use relationship support effect domperione RLS
mirtazapine domperione effect support relationship use symptoms RLS
mirtazapine domperione RLS
mirtazapine associated RLS
vitamin E lacking diet giving induced myodystrophy
E lacking diet giving induced myodystrophy
oral contraceptives hypertension association artery aneurysm dissecting
oral contraceptives hypertension association artery aneurysm
contraceptives hypertension association artery aneurysm dissecting
contraceptives hypertension association artery aneurysm
adriamycin ribose d induced myocardiopathy
Famotidine associated delirium
famotidine associated reported shown propensity cause delirium
famotidine cases report delirium
famotidine removal cleared delirium
thiopentone use associated eight risk 4 delirium
lindane induced role oxide convulsions
lindane dose elicited convulsion shortened increased incidence convulsion
lindane dose elicited convulsion
lindane dose convulsion decreased incidence convulsion
lindane dose convulsion
lindane dose convulsive
lindane seizures
galactose treatment prevents deficits cognitive
galactose treatment prevents deficits
streptozotocin treated rats prevents deficits cognitive
streptozotocin treated rats prevents deficits
glucose transport followed system dysfunction associated dementia type Alzheimer
glucose transport followed system dysfunction associated dementia type Alzheimer '
glucose transport followed system dysfunction associated dementia type s
glucose transport followed system dysfunction associated dementia type disease
glucose GLUT transport followed system dysfunction associated dementia type Alzheimer
glucose GLUT transport followed system dysfunction associated dementia type Alzheimer '
glucose GLUT transport followed system dysfunction associated dementia type s
glucose GLUT transport followed system dysfunction associated dementia type disease
glucose metabolism dysfunction associated dementia type Alzheimer
glucose metabolism dysfunction associated dementia type Alzheimer '
glucose metabolism dysfunction associated dementia type s
glucose metabolism dysfunction associated dementia type disease
galactose effects treatment deficits cognitive
galactose effects treatment deficits
streptozotocin deficits cognitive
streptozotocin deficits
STZ induced treatment deficits cognitive
STZ induced treatment deficits
galactose treatment month icv deficits cognitive
galactose treatment month icv deficits
STZ initiated treatment month icv deficits cognitive
STZ initiated treatment month icv deficits
STZ development prevented administration month icv deficits cognitive
STZ development prevented administration month icv deficits
galactose exposure have worth investigating improvement deficits cognitive
galactose exposure have worth investigating improvement deficits
isoproterenol injection induced injury myocardial
isoproterenol injection induced injury ischemic
isoproterenol injection induced injury
isoproterenol induced ischemia myocardial
isoproterenol induced ischemia
puromycin nephrosis
aminonucleoside nephrosis
puromycin aminonucleoside prevented inhibited angiotensin converting inhibitor proteinuria
aminonucleoside prevented inhibited angiotensin converting inhibitor proteinuria
PAN aminonucleoside prevented inhibited angiotensin converting inhibitor proteinuria
PAN injection induced Nephrosis
PAN rats neprotic
thiotepa chemotherapy polyneuropathy
thiotepa combination administration related toxicity neurologic
thiotepa combination administration related toxicity
TSPA combination administration related toxicity neurologic
TSPA combination administration related toxicity
methotrexate TSPA described toxicities Neurologic
methotrexate TSPA described toxicities
cytosine arabinoside IT methotrexate TSPA described toxicities Neurologic
cytosine arabinoside IT methotrexate TSPA described toxicities
arabinoside IT methotrexate TSPA described toxicities Neurologic
arabinoside IT methotrexate TSPA described toxicities
TSPA described toxicities Neurologic
TSPA described toxicities
MTX combination cause neurotoxicity
ara MTX combination cause neurotoxicity
C MTX combination cause neurotoxicity
TSPA agent fact spite cause neurotoxicity
galantamine well headaches
Valproate induced encephalopathy hyperammonemic
Valproate induced effect encephalopathy hyperammonemic
valproate treatment effect encephalopathy hyperammonemic
valproate describe revealed hyperammonemia
valproate describe revealed consciousness impaired
valproate describe revealed consciousness
D induced hyperactivity
amphetamine reduced induced hyperactivity
Amiodarone mass pulmonary
Amiodarone mass
Amiodarone mass glomerulonephritis membranous
Amiodarone mass glomerulonephritis
amiodarone developed mass lung
amiodarone developed mass
amiodarone lesion indicating containing composed suspected mass lung
amiodarone lesion indicating containing composed suspected mass
amiodarone lesion pulmonary
amiodarone lesion
amiodarone treatment complication suggests difficult diagnosis amiodarone lesion pulmonary
amiodarone treatment complication suggests difficult diagnosis amiodarone lesion
amiodarone diagnosis difficult suggests complication glomerulonephritis membranous
amiodarone diagnosis difficult suggests complication glomerulonephritis
amiodarone treatment complication glomerulonephritis membranous
amiodarone treatment complication glomerulonephritis
coumadin secondary hematomyelia Thoracic
coumadin secondary hematomyelia
